The Validity of Select Physical Activity Tracking Devices During Varying Physical Activity Intensity Ranges and Modalities in Persons With and Without Type One Diabetes by Yavelberg, Loren
THE VALIDITY OF SELECT PHYSICAL ACTIVITY TRACKING DEVICES DURING 
VARYING PHYSICAL ACTIVITY INTENSITY RANGES AND MODALITIES IN 
PERSONS WITH AND WITHOUT TYPE ONE DIABETES. 
 
 
LOREN YAVELBERG 
 
 
A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL 
FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTERS OF 
SCIENCE 
 
 
 
 
 
GRADUATE PROGRAM IN KINESIOLOGY AND HEALTH SCIENCE 
YORK UNIVERSITY 
TORONTO, ONTARIO 
 
SEPTEMBER 2016 
 
 LOREN YAVELBERG, 2016 
 
 
 
 
 
 
ii 
 
Abstract:  
The primary purpose of this study was to examine the validity of two high cost physical 
activity trackers, the Zephyr Bioharness
TM
, and the Metria Armband by Vancive,
 
to differentiate 
physical activity (PA) intensities and modalities using heart rate (HR), breathing frequency (BR), 
and energy expenditure (EE), when compared to indirect calorimetry using the Cosmed 
Fitmate
TM
 and the discrete component open circuit spirometry system. The secondary purpose of 
this study was to examine the validity of two low cost physical activity trackers the Garmin 
Vivofit2, and the Mio Fuse to differentiate between PA intensities and modalities using HR and 
EE, compared to indirect calorimetry from the Cosmed Fitmate
TM
 and the discrete component 
open circuit spirometry system. The study outcomes revealed that during the light-to-moderate 
intensity exercise session; i) the EE, as assessed by the Metria, was significantly different from 
the Fitmate with a mean overestimate of 0.64 kcals · minute
-1
; ii) the HR, as assessed by the 
Bioharness, was significantly different from the Polar  monitor (HR monitor used with FM) with 
a mean underestimate of 4.73 bpm and; iii) the BR, as measured by the Bioharness, was 
significantly different from the Fitmate with a mean underestimate of 9.49 breathes/minute. 
During the intermittent moderate-to-vigorous intensity exercise session; i) the EE, as assessed by 
the Metria, was significantly different from the Fitmate with a mean overestimate of 0.33 kcals · 
minute
-1
; ii) the HR, as assessed by the Bioharness, was significantly different from the Polar 
monitor with a mean underestimate of 0.6 bpm and; iii) the BR, as measured by the Bioharness, 
was significantly different from the Fitmate with a mean underestimate of 2.85 breathes/minute. 
During the vigorous-to-maximal intensity exercise session: i) the EE, as assessed by the Metria, 
was significantly different from the Fitmate with a mean underestimate of 1.78 kcals · minute
-1
; 
ii) the HR, as assessed by the Bioharness, was not significantly different from the Polar monitor 
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with a mean overestimate of 1.61 bpm and; iii) the BR, as measured by the Bioharness, was 
significantly different from the Fitmate with a mean underestimate of 5.61 breaths/minute. It is 
concluded that, despite the statistical significance compared to the criterion comparators, 
wearable technology that differentiates physical activity intensities and modalities is most 
promising for estimates of EE and HR. Therefore, whether persons are interested in; becoming 
habitually active, increasing the current level of PA, or improving quality of life with a chronic 
condition such as T1D, the higher cost PA trackers are the better choice given their ability to 
differentiate between PA intensities and modalities. 
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Chapter 1: Literature Review 
 
1.0 Introduction 
Primary Prevention and Secondary Disease Management with Physical Activity 
Participation 
The concept of habitual physical activity (PA) participation as a therapy for primary disease 
prevention and secondary disease management is far from novel, and dates back to the 1950’s 
with the work of Morris (Morris, 1953; Morris, 1953) and Paffenbarger in the 1970’s 
(Paffenbarger 1975; Paffenbarger, 1978). These studies assessed the relative risk of death 
resulting from physical inactivity and sedentarism (Powel, 1987; Berlin, 1990; Lee, 1995, 2000; 
Wannamethee, 1995; Kohl 2001; Oguma; 2002; Warburton, 2006). In addition, there has been 
undisputable evidence from more recent work discussing the benefits of habitual PA 
participation for primary disease prevention and secondary disease management. Such that, it has 
been proposed that there is a linear relationship between increases in PA participation and health 
status (Warburton, 2006).  PA is an umbrella term that encompasses all non-structured activities 
of daily living, leisure or recreational PA and structured exercise for the purposes of improving 
aspects of physical and physiological fitness (Bouchard, 1990, 1994).   
The increased prevalence of sedentarism and hypokinetic diseases along with the strong 
supporting evidence of the effectiveness of PA interventions, has underscored the need for 
prescriptive PA participation intervention strategies. The success of these intervention strategies 
are dependent on the individuals’ physical and physiological attributes, level of motivation, 
ability to stay committed, and the ability to accurately quantify the PA that the individual is 
participating in, as they may need to meet specific energy expenditure (EE) thresholds (Marcus, 
1994). Effective EE thresholds for reductions in incidence for type 2 diabetes has been 
documented to be as low as 500 kcal (Manson, 1992; Gregg, 2003), while increases of 2200 kcal 
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was associated with plaque reductions in persons with heart disease (Hambrecht, 1993; Franklin, 
2003). This evidence supports the importance of quantifying an individual’s EE from a PA bout, 
as well as the importance of a customized PA regime.  
Furthermore, the level of motivation an individual’s ability to stay committed will affect 
their adherence and compliance to the PA prescription, and in turn the effectiveness of the PA 
intervention.  To facilitate this, it has been shown that self-regulation strategies, such as self-
monitoring, goal-setting, reinforcements, and self-corrective actions increase PA participation in 
a variety of populations (Bandura, 1991). All of the above could be effected by a number of 
different factors that a wearable PA monitoring and/or motivational device could provide. Based 
on the Transtheoretical model of behavior change, it is known that a person will commonly 
progress through six stages of change; precontemplation, contemplation, preparation, action, 
maintenance, and termination (Prochaska, 1997). The time spent in each of the respective stages 
does not have to be linear, and an individual may progress through the first 3 stages rather 
quickly until they find themselves in the action phase (Marcus, 1994). An individual’s stage of 
change refers to their readiness to engage in regular PA. The process of change includes’ five 
cognitive and behavioral strategies that one uses as they progress from the first to last stage 
(Marcus, 1992). Wearable technology that monitors or promotes PA may serve as a critical tool 
to keep an individual motivated to support ones cognitive and behavioral processes toward 
achieving a behavior change. It has been demonstrated that real-time data visualization from a 
wearable technology device during PA provides enhanced awareness and motivation to the 
wearer. Additionally, when the output of these devices is integrated with a social sharing 
platform, the level of motivation is further enhanced (Consolvo, 2006; Toscos, 2006; Ali-Hasan, 
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2006; Lin, 2006). Emerging evidence supports that both conscious awareness and PA 
participation tracking reinforce behavior change.  
The ability of wearable technology devices to quantify volume of PA is based on the 
manufacturers proprietary formulas and the testing that these devices undergo during 
development. Although the precision of these devices has been questioned, they are considered 
to be sufficiently accurate for use with populations interested in increasing their PA participation 
(Albinali, 2010).  These devices can also aid in understanding and achieving exercise 
prescriptions. The global public health messages recommend that individuals should engage in 
thirty minutes or more of moderate intensity PA on most days of the week, accumulating 1000-
2000 kcal/week, should reduce their sitting time, as well as, maximize their activities of daily 
living (Giannuzzi, 2003; Gledhill, 2003; Warburton 2006). Throughout the day, an individual 
encounters different physical demands, thereby varying their daily EE. Therefore, if an 
individual was to become aware of their increase in sedentarism, they may be more inclined to 
proactively participate in PA, if they are outfitted with a device that provides both visual and 
physical alerts (Consolvo, 2006; Toscos, 2006; Ali-Hasan, 2006; Lin, 2006). 
 For the purposes of secondary disease management, PA and exercise prescriptions are 
strongly dependent on the exercise-related risk. Risk stratification can be accomplished by 
applying evidence based screening tools such as the annually updated PAR-Q+ (e.g. 2015 PAR-
Q+ and when applicable, the ePARmed-X+ (www.eparmedx.com) (Balady, 2000; Bredin, 2013; 
Fletcher, 2001). Individuals stratified as low-risk may be prescribed a PA and/or exercise 
prescription similar to that of a healthy individual. Moderate-to-high risk individuals should 
follow a strictly individualized PA and exercise prescription which is characteristic of a lesser 
intensity, thus a lower accumulated EE. Nonetheless, cumulative small amounts of PA are 
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beneficial in order to enable maintenance of independent living and counteract any co-
morbidities (Gledhill, 2003). Providing individuals with chronic conditions with the ability to 
monitor their PA intensity and EE via wearable technology can greatly improve the efficacy of 
secondary prevention. It is known that with as little as 500 kcal/week individuals can see 
improvements by as much as 20% in some physiological health markers, as illustrated in Figure 
1. Figure 1 illustrates that much of the improvement in some health benefit indicators is achieved 
at lower volumes of physical activity participation (e.g., triglycerides and blood pressure), while 
much of the improvement in other health benefit indicators comes at higher volumes of 
participation (e.g., high-density lipoproteins). The ‘volume’ of physical activity is simply the 
sum of all bouts of physical activity, regardless of how short the duration.  Assuming a person 
expends 100 kcal/15 minutes. Figure 1 also illustrates how the Volume of Physical Activity in 
kcal/per week relates to daily and weekly time commitment (over 5 days) (Gledhill, 2003, 
Jamnik 2015) 
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Figure 1: Theoretical relationship between physical activity and various determinants of 
health status as proposed by Gledhill and Jamnik. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
kcal/week 500 1000 1500 2000 2500 3000 
Minutes/day 15 30 45 60 75 90 
Minutes/week 75 150 225 300 375 450 
Hours/week 1 ¼ hr. 2 ½ hr. 3 ¾ hr. 5 hr. 6 ¼ hr. 7 ½ hr. 
 
Reprinted with permission – Physical Activity & Lifestyle ‘R’ Medicine. Jamnik and Gledhill 
(2016) 
 
Although there are many acute and chronic benefits associated with PA participation both the 
quantity and quality of the PA play integral roles in the benefits that can be realized. The 
exercise prescription must be mode and load dependent which corresponds with the FITT 
principle; frequency, intensity, time, and type (Pollock, 1998). More importantly, the exercise 
bout should be; specifically geared towards the individual’s goals, include variation and 
periodization to minimize desensitization and maximize training adaptations (Ratamess, 2009). 
All of the above principles must be considered when delivering a customized PA and/or exercise 
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prescription protocol, as different conditions, diseases and co-morbidities will require varying 
stimuli or dosage to maximize the benefits of the PA (Warburton, 2006). 
Type one diabetes (T1D) is a common autoimmune disease, which is typically diagnosed 
in children as young as ten years of age. This is a critical time in a child’s growth and 
development and when the child begins to adopt habits which they would employ for the 
remainder of their lives. However, T1D can be diagnosed as early as the first year of life. 
According to the Canadian Diabetes Association, there are 2.7 million Canadians living with 
diabetes or prediabetes and 5-10% (135,000 - 270,000) have T1D (DIAMOND PROJECT 
GROUP 2006, DiaMond 2000; CDA). Furthermore, the Public Health Agency of Canada has 
reported that Canada was found to have one of the highest incidence rates of T1D for children 
under 14 years of age (DIAMOND PROJECT GROUP 2006, DiaMond 2000). All persons with 
T1D depend on a customized insulin injection regime, as the individuals’ pancreas is no longer 
able to produce insulin. The inability to produce insulin is a direct result of the autoimmune 
destruction of the pancreatic beta-cells (Alberti, 1998; Maahs, 2010; Shugart, 2010). As the cells 
begin to diminish in number, the individual's pancreas loses the ability to produce and secrete 
insulin, resulting in insulin deficiencies and dysglycemia complications. Unfortunately, the field 
of diabetic management is far from black and white when it comes to standardized insulin 
dosing. Individuals with T1D must learn and adapt to their body’s glycemic fluctuations. There 
are many documented complications associated with extreme blood glucose levels, which 
exacerbate the development and severity of future diabetes related conditions (Chu, 2011). The 
ever-present challenge to attenuate glycemic fluctuations underscores the need for appropriate 
insulin dosing. Some of the major hurdles associated with insulin injections include; injecting too 
much or too little, as well as the events that follow the last insulin dose administration. 
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 Technological advancements and medical engineering laboratories are developing 
devices that continuously monitor blood glucose levels and communicate with an individuals’ 
insulin pump. This device is commonly known as a continuous glucose-monitoring device 
(CGM), which is designed for persons with T1D to avoid or minimize the traditional finger 
prick-lancet method. The CGM design has the potential to eliminate fears of 
hypo/hyperglycemia in T1D, specifically during PA participation, as it could remove the 
inconvenience of individuals having to temporarily suspend their exercise bouts to measure their 
blood glucose levels. While, it is widely acknowledged that regular PA participation is important 
for preventing and managing a wide range of chronic diseases and conditions including T1D 
(Bouchard, 1988, 1992; Kesaniemi, 2001). In the context of T1D, PA participation is a paradox 
owing to the unpredictable and consequent hypo/hyperglycemic outcomes. Although this device 
seems to be highly convenient and safe, there are a few shortcomings to this technology that 
should be noted. The major limitation of the CGM is its accuracy, which is related to method of 
measurement (Vaddiraju, 2010). The accuracy of the CGM is affected by the methods of 
measurement, as the device only assumes blood glucose levels based on the current (partial) 
presence of glucose concentration which has diffused into the individuals’ interstitial fluid, from 
the bloodstream (Boyne, 2003, Kulcu 2003).  
The National Institute of Health (NIH) and other funders are currently supporting the 
development of a closed-loop artificial pancreas (AP), which is a device that acts similarly to an 
insulin pump, but does not require any user-input, thereby minimizing the risks associated with 
diabetic hypo/hyperglycemia and other related complications (Riddell, 2015; Turksoy, 2015). 
Ideally, in order for the AP to accurately function it must be paired with a CGM and a PA 
intensity monitoring device. It should be noted that the applications of PA intensity monitoring 
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devices are not limited to T1D. These PA intensity monitoring devices will undoubtedly become 
increasingly essential in primary prevention and secondary disease management across the 
lifespan. 
 
1.1 Overview of Physical Activity  
 PA encompasses activities of daily living, active transport, structured exercise, 
specialized skilled movement, and sports participation (WHO, 2010). The inherent rate of energy 
demand imposed by PA participation aligns with “global intensity spectrum descriptors” such as: 
very light, light, light-to-moderate, moderate, moderate-to-vigorous, vigorous and vigorous-to-
maximal and maximal (Gledhill, 2003; Jamnik and Gledhill 2015; Norton, 2010).  The body’s 
ability to effectively respond to the varying intensities along the PA spectrum is highly 
dependent upon the continuous interplay between the aerobic and anaerobic metabolic systems 
(Gastin, 2001). Although both metabolic systems contribute to total metabolism, the greater or 
lesser shared reliance of the two metabolic systems in meeting the energy requirements is 
dictated by both the PA intensity and duration.  At low continuous rates of energy demand the 
aerobic metabolic system is dominant, and as the rate of energy demand progressively increases 
there is a concomitantly greater reliance on both the aerobic and anaerobic metabolic systems 
regardless of whether the PA is continuous or intermittent in nature (Åstrand, 2003). In 
summary, the practice of stratifying PA as aerobic, aerobic-anaerobic versus anaerobic is simply 
intended to underscore the dominance of an energy system in resynthesizing the energy required 
to meet the imposed energy demand.  It is necessary to underscore that use of metabolic 
descriptors to classify PA intensities, while convenient, is overly simplistic and can be 
misleading. 
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1.2 Benefits of Physical Activity  
The benefits of PA for persons with and without T1D should be noted as they largely 
assist in many positive health outcomes for both populations. The benefits of habitual PA are the 
same for persons with and without T1D (Chu, 2011; Guelfi, 2005). The common T1D specific 
benefits include; increased glucose control plus management, the effectiveness of insulin 
(Herbst, 2007; Riddell, 2004), improved glucose uptake (Norris, 1990) resulting in lower blood 
glucose levels plus glycated hemoglobin (HbA1C), and reduced risks for diabetic complications 
such as nephropathy, retinopathy, and neuropathy (CDA). Other non-disease specific benefits 
include, but are not limited to; improved body mass management, reduced risks for osteoporosis, 
reduced risks for cancer, increased quality of life (QOL), improved self-esteem. (Warburton, 
2006), improved blood pressure (Chu, 2011), and improved blood lipid profile (Campaigne, 
1985; Laaksonen, 2000). 
 
1.3 Aerobic Physical Activity  
Typically, aerobic activity is characterized as light-to-moderate and moderate-to-vigorous 
intensity PA, which may be performed continuously or intermittently, but dependent on an 
individual’s aerobic capacity and power. An example of light-to-moderate intensity PA would be 
purposeful walking at a 15 to 20-minute mile pace 3.5 – 3.7 mph (5.6- 5.9 km/h) or light jogging, 
5 - 6 mph (8 -10 km/h), which would be associated with an intensity around 3 to 5 metabolic 
equivalents (METs), 50 to 75 percent of an individual’s age-predicted maximum heart rate, 20 – 
59% of heart rate reserve, or up to 50% of an individual's VO2 max, or 10 - 13 out of 20 on the 
original the Borg subjective Rating of Perceived Exertion scale (RPE) (Åstrand, 2003; Jamnik, 
2011; Warburton, 2006; Borg, 1992).  
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1.4 Aerobic-Anaerobic Physical Activity  
 Aerobic-anaerobic plus anaerobic PA classically consists of intermittent moderate-to-
vigorous and vigorous-to-maximal intensity bouts of PA such as sprints or maximal lifts, 
interspersed with light-to-moderate intensity PA or a passive recovery period. This activity is 
associated with moderate-to-vigorous intensities of 6 – 7 METs and corresponds to 50 to 75 
percent of an individuals’ VO2 max, and vigorous-to-maximal intensities corresponds to upwards 
of 6 to 10+ METs and corresponds to 75 to 100 percent of an individual's maximum heart rate or 
approximately 60% or more of an individual's maximal oxygen uptake (VO2 max), or 16 - 20 out 
of 20 on the original the Borg subjective RPE scale. The energy demand required upon the 
initiation of such activity is fulfilled by combination of the anaerobic and aerobic metabolic 
systems. The dominance of the anaerobic metabolic system allows for high muscle phosphagen 
and anaerobic glycolysis to meet the high-energy demands throughout the intense bout of PA 
(Åstrand, 2003). 
 
1.5 Monitoring PA: Established and Emerging Self-Wear Technology and Accelerometers   
 Recently there has been an exponential increase in the popularity and implementation in 
self-wear technology (Murakami, 2016). Self-wear technology can be divided into different 
categories including PA trackers, sleep trackers, and sleep management devices. Some self-wear 
devices have the ability to perform under multiple categories. The measurements provided by 
this technology are primarily used to quantify an individual’s EE and provide an overview of 
their PA patterns (Achten, 2003). Self-wear technology devices are designed to measure an 
individuals’ EE, keeping individuals motivated and on track to achieving their fitness training 
goals. There are an abundance of products on the market which vary in their respective 
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accuracies and measurement techniques (device name, mean absolute percent error); BodyMedia 
Fit 9.3%. Fitbit Zip 10.1%, Fitbit One 10.4%, Jawbone Up 12.2%, Actigraph 12.6%, DirectLife 
12.8%, NikeFuel Band 13.0%, and Basis B1 Band 23.5% (Lee, 2014) 
Typically, the devices operate using proprietary formulas and assumptions, which are 
based on the wearers’ heart rate (HR), accelerometry (step counts or CPM) or a combination of 
the two which associate with common relative PA intensities as described using percent heart 
rate reserve, percent HRmax, RPE, and METs (Table 1). To date, next to indirect calorimetry, 
electronic HR monitors have proven to be the most accurate and reliable for monitoring PA 
intensity and EE (Swain, 1997; Achten, 2003). Additional technologies attempt to capture other 
parameters such as skin temperature, near body ambient temperature, breathing 
rates/frequencies, heat flux, sweat rate and accelerations in triaxial planes to also quantify EE. It 
is important to note, that the major inherent limitations of these devices lies in their accuracy and 
reliability (Murakami, 2016).  
Table 1: Harmonization of different expressions of relative intensities for aerobic exercise 
prescription for activities lasting 30 to 60 min. 
 
 
 
 
 
Reprinted with permission – Jamnik 2011 
Accelerometry-based devices measure the body’s acceleration in up to three planes, and 
are commonly referred to as triaxial accelerometers. The three orthogonal planes are 
anteroposterior, mediolateral, and vertical, thus, attempting to account for individuals’ 
acceleration in all planes of movement. Most accelerometers rely on multiple piezoelectric 
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sensors to complete these measurements (Chen, 2005). The piezoelectric acceleration sensor 
detects acceleration when the sensor undergoes a degree of deformation based on its internal 
components. The sensor is able to differentiate in accelerations based on the geometry (cross-
sectional area and length), material property (stiffness), and the positioning of the seismic mass 
on its beam. In order for the accelerations to be measured in various planes, several 
unidirectional translational accelerometer units must be mounted orthogonally to one another. A 
major limitation of most piezoelectric accelerometers is that they can only reliably detect 
dynamic events (Togowa, 1998; Chen, 2005). For example, the accelerometers may not 
accurately detect movement when a person is exercising on a stationary cycle ergometer or a 
road bike.   
Although these devices are not as accurate as traditional laboratory practices, and may 
never be, there is certainly no doubt about the accessibility and practicality of these efficient and 
affordable devices. For monitoring PA intensity in the general population, the information that is 
provided with the respective degree of error is sufficiently accurate to draw some conclusions 
(Lee, 2013; Lee, 2014). Thus, these devices can successfully serve as valuable tools for primary 
prevention and secondary disease management with PA participation. Given the well 
documented benefits of habitual PA participation on, cardiovascular disease, peripheral arterial 
disease, diabetes, cancer, hypertension, obesity, depression and osteoporosis) and premature 
death, (Powel, 1987; Berlin, 1990; Lee, 1995, 2000; Wannamethee, 1995; Kohl 2001; Oguma; 
2002; Warburton, 2006) it becomes evident that the pairing of PA participation with wearable 
technology may enhance disease prevention and management. 
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1.6 Blood Glucose Instabilities in T1D and Exercise 
 Given the importance of PA participation, it is imperative to understand the potential 
glycemic fluctuations and triggers a person with T1D could encounter. A physically active 
individual with T1D can experience hypo- or hyperglycemia dependent on PA modality and 
intensity. In general, when persons participate in PA, there are a number of physiological 
responses and metabolic pathway adjustments which allow for the energy demands to be met. 
These include, but are not limited to, increases in VO2, rate of lactate production plus clearance, 
and motor unit recruitment which collectively work towards supporting the resynthesis of 
adenosine-triphosphate (ATP) (Knuttgen, 1972). For most PA, the energy demands are typically 
met through the breakdown of muscle glycogen to glucose via aerobic and aerobic-anaerobic 
metabolic pathways (Saltin, 1971). For persons without T1D, the maintenance of blood glucose 
is accomplished by counter-regulatory responses of glucagon and insulin. The secreted glucagon 
triggers the release of glucose from the liver, into the bloodstream, via the breakdown of 
glycogen in the Cori cycle. This process of hepatic glucose production is mediated by insulin 
(Gallen, 2005; Landt, 1985; Wasserman, 1994; Zinker, 1999). As all individuals with T1D lack 
the ability to produce insulin, they must rely on exogenous injections to supply it. Therefore, it is 
vital to the exercising individual, with T1D, to ensure adequate amounts of insulin prior to 
initiating any form of PA.  
It is known, that sustained light-to-moderate intensity aerobic PA typically results in 
hypoglycemia in persons with T1D (Guelfi, 2005). Given the presence of too much insulin, the 
individual could experience an accelerated rate of glucose uptake into the muscle (Riddell, 2006; 
Toni, 2006; Tonoli, 2012). In this instance, hypoglycemia is as of a result of the depletion of 
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muscle carbohydrate stores, which is the primary substrate needed to resynthesize the ATP, 
required for the sustained low-to-moderate intensity bout of PA.  
Hypoglycemia is characterized as low blood glucose levels; usually less than 70 mg/dl or 
3.9 mmol/l (ADA, 2015). Hypoglycemia in persons with T1D can be induced by PA 
participation, too much insulin, and/or lack of glucose ingestion (Cryer, 2003). The symptoms of 
hypoglycemia are, but are not limited to; nervousness, anxiety, irritability, confusion, shakiness, 
lightheadedness, hunger, nausea, blurred or impaired vision, seizures, coma, and death (National 
Institute of Diabetes and Digestive and Kidney Diseases, 2008). Unfortunately, in the short term, 
hypoglycemia is far more severe compared to high blood glucose levels (hyperglycemia). In 
order to quickly rebound the hypoglycemic state, the individual must ingest 15 grams of fast-
acting simple carbohydrates, or if unconscious, exogenous glucose must be administered (CDA, 
ADA 2015). The importance of safe blood glucose monitoring and management is critical for the 
health, well-being, and quality of life of individuals with T1D. The underlying factors of 
hypoglycemia could be any single variable or combination of the following variables; excessive 
carbohydrate depletion, lack of carbohydrate ingestion prior to activity, or hyperinsulinemia 
(Tuominen, 1995, Rabasa-Lhoret, 2001). 
In contrast, the performance of aerobic-anaerobic or anaerobic PA typically demands a 
vigorous-to-maximum effort, inherently resulting in hyperglycemia and in an extreme situation, 
ketoacidosis (Jain, 2006; Riddell, 2006; Toni, 2006; Tonoli, 2012). Evidence suggests that the 
observed increases in blood glucose during anaerobic or anaerobic-aerobic activity PA are a 
consequence of the interplay between energy resynthesis and the presence of stress hormones 
such as epinephrine. Hyperglycemia is characterized by fasting blood glucose levels above 126 
mg/dl or 7 mmol/l (ADA, 2015). In persons with T1D, the consequent hyperglycemia is 
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attributed to insulin insufficiency (Purdon, 1993, Sigal, 1996, Marliss, 2002, Wasserman, 2002, 
Bussau, 2006).  Given the insulin insufficiency, and resultant inability of muscles to take up 
glucose, this results in a greater reliance on free fatty acids for ATP resynthesis. In extreme 
situations, the increase of free fatty acid breakdown results in the production of ketone 
byproducts, thus initiating ketoacidosis. An unchecked ketoacidotic state will hinder PA 
participation due to the decrease in blood pH (Jain, 2006; Riddell, 2006). A person with T1D can 
experience hyperglycemia as of a result of diet, i.e. too much carbohydrate ingestion, and/or a 
lack of insulin, or vigorous or maximal intensity PA including exercise, or stress. The symptoms 
for severe hyperglycemia include shortness of breath, fruity breath, increased thirst, and frequent 
urination. If hyperglycemia goes untreated, persons with T1D can become ketoacidotic, which 
could potentially cause a diabetic shock or coma (WHO, 2016). 
Emerging evidence supports that the participation in intermittent moderate-to-vigorous 
intensity and vigorous-to-maximum intensity bouts of PA appear to be more effective in 
attenuating undesirable glycemic fluctuations for T1D (American Diabetes Association, 2004; 
Bussau, 2006; Bussau, 2007; Robertson, 2009). The PA bout should ideally consist of an 
individual performing whole body aerobic PA interspersed by whole body anaerobic- aerobic 
and anaerobic PA to offset the negative effects of each activity which could induce 
hypo/hyperglycemia. Therefore, it is imperative for physically active persons with T1D to 
understand the associated glycemic risks and the respective strategies to attenuate the potential 
adverse effects (Guelfi, 2005).  
  
16 
 
Chapter 2: The Accuracy and Sensitivity of Select Exercise Intensity Devices During 
Varying Exercise Modalities in Persons With and Without Type One Diabetes. 
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2.0 Purpose 
Advances in PA “sensing” self-wear technology have emerged that quantify movement via, 
accelerometry, global position satellite, etc. to gauge the relative PA intensity. There is an 
abundance of products on the market which all vary in their measurement techniques, costs and 
accuracies (e.g., Polar and Garmin HR monitors, Fitbit, Nike FuelBand, Sense-Wear, Jawbone). 
This study was precipitated by the needs of persons interested in developing an artificial 
pancreas (AP). These persons were seeking to obtain electrical signals that aligned with real-time 
physiological responses, obtained during varying PA intensities and modalities. These findings 
also play an integral part in customized primary disease management, secondary disease 
prevention, PA prescriptions, the enhancement of current knowledge of EE, HR, BR, and shine 
light on the novel uses of currently available technology and wearable technology. Therefore, the 
purpose of this study was to evaluate the validity of EE, HR, BR from two high cost pieces of 
wearable technology which could potentially be used in a future AP investigation, along with 
two other low cost consumer-based PA activity trackers, during varying PA intensities and 
modalities. Given the effects of PA on glucose fluctuations in persons with type 1 diabetes (T1D) 
depending on the volume of PA (i.e., aerobic, anaerobic, mixed), this variability in glucose 
responses to PA makes the development of AP systems challenging and particularly underscores 
the need for accurate PA intensity “sensing” self-wear technology. It was important to assess the 
accuracy of these devices in both healthy and clinical populations for targeted primary 
prevention and secondary disease management. The two pieces of high cost hardware included 
the Zephyr Bioharness and the Metria Armband, while the two low cost consumer-based 
products included the Garmin VivoFit 2 and the Mio Fuse. The aim was to examine the validity 
of these activity trackers during varying exercise intensities plus modalities in persons with and 
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without T1D using EE, HR, and BR. This was accomplished by comparing the primary outcome, 
EE, using indirect calorimetry via the open circuity spirometry from the discrete component 
system and a metabolic unit (Cosmed Fitmate, Cosmed, Italy). The HR from the PA tracking 
devices was compared to the HR obtained with the Polar Unit (Polar Electro, Kemeple, Finland). 
The primary outcome of interest was EE obtained from each of the devices while the secondary 
outcomes included HR and BR. Given that EE is a common variable in all of the devices it was 
used as a measure of primary outcome (Table 2). Table 2 summarizes the variables that are 
measured by each device. For this investigation: i) the discrete component system and the 
Fitmate measured HR, EE, BR and oxygen consumption were measured, ii) the Metra only 
measured EE, iii) the Bioharness measured HR and EE, iv) the Garmin Vivofit2 measured EE, 
and v) the Mio Fuse measured EE. All devices were compared to the criterion standard variables 
assessed using the discreet component open-circuit spirometry system in the left column. 
Table 2: Variables that are measured by each device. All devices were compared to the 
criterion standard in the left column. 
Measured Variables 
Variable Discrete Component 
System 
Fitmate Metria Bioharness Garmin VivoFit2 Mio Fuse 
Heart Rate (bpm)       
Energy Expenditure (kcal/min)    (KJ)    
Breathing Rate (b/m)       
Oxygen Consumption       
Heart Rate Variability       
Accelerometry       
Sleep Quality + Duration       
Posture       
Peak Acceleration       
Skin Temperature       
*Energy expenditure is reported but not recorded on the Bioharness, along with Heart Rate from the Garmin 
Vivofit2 and Mio Fuse. 
 
2.1 Hypothesis 
 
It was hypothesized that EE recorded from the devices would accurately differentiate PA 
intensities within all wearable technology devices. The secondary outcomes, HR, BR and Direct 
VO2, were used to confirm the PA intensity differentiation.  
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2.2 Methods 
All protocols were reviewed and approved by the Human Participants Review Sub-Committee at 
York University’s Office of Research Ethics. Throughout the study there were no adverse events 
to report on. 
 
2.2.1 Study Participants and Requirements 
A total of twenty-five male and female study participants were recruited including 8 
persons with T1D.  The study participants were between the ages of 18-55 (24.75 ± 7.58). Those 
participants with T1D must have been using an insulin pump for at least six months prior to 
participating in the study, and were not part of any other clinical trials or taking medications for 
any reason which would alter their diabetes management. Study participants did not have any 
physical ailments which would contraindicate participation in the study (e.g. cardiomyopathies, 
neuropathy, other diabetes-related complications), and were screened by a certified exercise 
physiologist using the evidence-based screening tools, the 2015 PAR-Q+ and ePARmed-X+ 
(www.eparmedx.com) for exercise contraindications and risk stratification.   
 
2.2.2 Laboratory Based Physical and Physiological Fitness Assessment 
Once recruited, the participants were randomly assigned to the PA order, to minimize 
order effects.  There was a maximum of 5 test days in the laboratory.  On the initial test day each 
participant underwent an incremental-to-maximal effort treadmill test for the determination of 
aerobic fitness or power (VO2 max) using the criterion discrete component system (n=18) or 
Fitmate (n=19) open circuit spirometry. A subset of the study participants (n=14, 7 males and 7 
females), who had their VO2 max determined by the discrete component system repeated the 
incremental-to-maximal effort treadmill test using the Fitmate metabolic unit, on a fifth day. This 
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was used to confirm that the measured variables from the Fitmate metabolic unit were both 
accurate and reliable. This permitted the Fitmate metabolic unit to be used as the criterion device 
for the measurement of interest during the exercise sessions.  In addition, anthropometric data 
including height, body mass, percent body fat, skinfolds, waist circumference and pre-exercise 
blood pressure were collected. Study participants had their body mass measured upon each visit 
(Seca Alpha Scale, Modell 770, Germany).  Percent body fat was measured, without shoes, using 
bioelectrical impedance analysis (Tanita scale, model TBF-612, Arlington Heights, Illinois). 
Height was measured without any footwear, using a wall-mounted stadiometer. Waist 
circumference (WC) was measured using the standard National Institute of Health (NIH) 
protocol, which entails the tape measure being placed around the waist, on the skin, at the level 
of the iliac crest. Skinfolds were measured using Harpenden fat calipers (Baty International, 
Burgess Hill, England) according to the PALM (Jamnik and Gledhill, 2015). The skinfold sites 
included the Tricep, Bicep, Subscapularis, Iliac Crest and Medial Calf. The composite body 
composition was derived from the measurements of body mass index (BMI) (Metric: BMI= 
 𝑘𝑔
ℎ (𝑚2)
 , English: BMI= 
 𝑙𝑏
ℎ (𝑖𝑛2)
∗ 703), sum of the five skinfolds (SO5S), and the NIH WC. In 
summary, the BMI and SO5S provide an indication of the overall amount of body fat and the 
WC provides information on visceral or central adiposity. The composite body composition 
score is used to estimate the health-risk attributable to body composition and this is 
accomplished by using graduated WC and SO5S within and across each BMI category (Jamnik 
and Gledhill, 2015). 
 Pre-exercise blood pressure and pulse rate measurements were determined in the seated 
position, in a private room, using an automated device (BpTRU Medical Devices Ltd. BC 
Canada).  Following a five-minute sitting rest period, the BpTRU™ recorded six sequential 
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measurements, one minute apart. The BpTRU™ device generated average values for the pre-
exercise systolic plus diastolic blood pressures and pulse rate using the last five of the six 
measurements.  Although not required, all hypertensive values would have been re-evaluated 
using the auscultatory blood pressure method. 
 
2.2.3 Data Collection Process  
The incremental-to-maximal effort treadmill test for the determination of VO2max 
followed the same loading sequence for all participants, but was terminated based on their 
respective capacities. The protocol was designed with a built in warm-up, and workload was 
increased every two minutes. The protocol was initiated at 3.5 mph (5.6 kph) - 1% elevation and 
then progressed accordingly; 5 mph (8.0 kph) - 1% elevation, 6 mph (9.7 kph) - 1% elevation, 
6.5 mph (10.5 kph) - 1% elevation, then subsequent workloads consisted of the same speed (6.5 
mph) with increases of 2% in elevation every 2 minutes. When the study participants were no 
longer able to continuously run, an active recovery was initiated, which allowed them to slow 
down to a lower intensity of 3.5 mph - 1% elevation for 2 minutes. Subsequently, the attainment 
of VO2 max was confirmed using a discontinuous protocol. Thus, the participants exercised at 
higher workloads for 2 minutes, followed by another active recovery. This protocol sequence 
was repeated until the VO2 of the subsequent workload was equal to or lower than the previous, 
indicating maximum oxygen intake (Lupton, 1923, Gledhill, 1994; Howley, 1995). This can also 
be referred to as supramaximal testing, where the individual was not taken to a peak, but rather a 
true max where the VO2 of the more difficult task was lower than the previous (Jacobs, 1983; 
Gledhill 1994). The VO2 was determined from measurements obtained during the last thirty 
seconds of each workload via direct analysis of mixed expired gases. The initial treadmill test 
was completed using the gold-standard discrete open circuit spirometry Tissot tank system, while 
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the final test was completed using the Fitmate metabolic unit, Cosmed Fitmate, in order to ensure 
validity in the hardware.  
 The discrete open circuit spirometry system was comprised of; a 120L Tissot gasometer 
collection tank (Warren E Collins LTD. Braintree, Massachusetts), rapid response oxygen and 
carbon dioxide gas analyzers (Applied Electrochemistry, Model S-3A and CD-3S, Sunnyvale, 
California), a hose, two-way y-valve (Ewald Koegal Co, San Antonio Texas), mouthpiece and 
nose plugs. The mouthpiece was positioned between the participants’ gums and teeth and they 
were required to breathe in and out of the mouthpiece throughout the VO2 collection period with 
their noses plugged. The Y-valve allowed the participants to freely inhale atmospheric air, then 
directly exhale air into the hose then tank, where the gasses mixed and collected. Once the 
expired gases were collected they were then analyzed using the gas analyzers which worked in 
tandem to each other. The collected variables; minute ventilation, fractions of expired carbon 
dioxide and oxygen, were then used to calculate the participants’ VO2. The other variables of 
interest included BR (b/m), HR (bpm), and EE (kcals) was estimated from VO2 L·min
-1
, where 
for every liter of consumed oxygen the EE is approximately 4.86 kilocalories per minute 
(Péronnet, 1991). The VO2 max test was terminated if the study participant could no longer 
complete the workload as a result of volitional fatigue, or if the above VO2 max criteria was met. 
This was to be determined by the qualified exercise physiologist present at the time.  
 The portable metabolic unit (Fitmate), worked similarly to the discrete component system 
by using expired gas analysis, but differed in gas collection and calculation techniques. The 
study participant was outfitted with a face mask which was held in place by a headpiece. While 
the study participant was exhaling, a flowmeter and oxygen sample line, attached to the face 
mask, collected data on breathing rate, volume of air, and the fractional concentration of oxygen. 
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Unlike the discrete component system, the Fitmate only analyzed the expired oxygen and 
assumed the associated carbon dioxide concentration based on proprietary formulas. The Fitmate 
metabolic unit was also able to internally calculate the participants’ provided breath-by-breath 
VO2. The other variables of interest included BR (b/m), HR (bpm), and EE (kcals) was estimated 
from VO2 L·min
-1
, where for every liter of consumed oxygen the EE is approximately 4.86 
kilocalories per minute (Péronnet, 1991). The identical test termination criteria were applied, as 
stated above. The criterion pulse (heart) rate was measured throughout using a Polar HR monitor 
(Polar Electro, Kempele, Finland).  
 All study participants were instrumented with the; i) Bioharness chest strap for the 
measurements of HR (bpm) and BR (b/m), ii) Metria armband for the measurement of EE (kJ), 
iii) and the Garmin chest strap or Mio wrist band for the measurements of HR (bpm) and total 
EE (kcals). The Metria Armband was worn on the study participants’ non-dominant upper arm 
and collected information on the individuals’ Skin Temperature, PA Intensity, Activity Levels, 
and EE. While the Zephyr Bioharness, was worn on the study participants’ upper body in the 
form of t-shirt or chest strap and collected information on HR, HR variability, BR, Posture, 
Activity Level, Peak Acceleration, Speed and Distance. Both devices are non-invasive, and 
persons with T1D exercised while wearing their own insulin pumps in addition to the wearable 
technology. Both consumer-based fitness trackers also measure HR and EE. The Garmin 
VivoFit2 measures HR through a conventional chest strap, while the Mio fuse measures HR 
through reflection photoplethysmography using green 530nm wavelength light. 
Following the initial test day, each group participated in the remaining 4 activity days in a 
differing order. The purpose of this was to exclude any training order effects. The exercise days 
consisted of a continuous light intensity treadmill based continuous exercise session or a 
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calisthenics-based circuit exercise session. The exercise intensities were predetermined for each 
activity day, based on the participants' VO2 max, as determined on the initial visit. The study 
participants repeated either the intermittent circuit or continuous light activity days on the 
remaining two activity days (Figure 2).  This ordering of activity would allow the researchers to 
monitor accuracy on a test-retest basis. All measurements and exercises were performed in the 
Human Performance Laboratory at York University. 
Figure 2: Summary of Laboratory Measures 
 
  
 
 
 
 
 
 
 
 
VO2, HR and RPE were continuously measured during the continuous light-to-moderate 
intensity PA which consisted of walking on the treadmill for 40 minutes, at a speed and grade 
that elicited 40-50% of the study participant's VO2 max. Blood glucose was measured every ten 
minutes for participants with T1D. On a subset of study participants, finger prick blood lactate 
was measured every ten minutes to confirm the PA intensity (Lactate Scout, EKF Diagnostics, 
 
 
  
T1D repeated circuit  
Non-diabetics repeated either circuit or light 
Anthropometry: 
Height (cm), Body Mass (kg), Body Composition 
Non-T1D repeated incremental to maximum 
effort VO2 protocol 
 Incremental to maximum effort VO2 protocol 
 
T1D and non-diabetic randomly assigned to complete either light-to-moderate continuous or moderate-to-vigorous intensity circuit first 
 
Study participants completed fitness assessment 
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Wales, UK). The exercise collection was terminated based on a blood glucose cut-point of 3.5 
mmol/l.  
VO2, HR and RPE were also measured throughout the circuit activity day which 
included:  walking on a treadmill for 4 minutes, performing a circuit of the following exercises:  
marching on the spot with high knees (using the arms) 45 sec; squats with a front sweep (reps/60 
sec); 4 Jumping Jacks; quadruped (aka as the bird dog) (30 sec); 2 Jumping Jacks; 4 push-ups 
followed by a 20 sec prone forearm plank; marching on the spot with high knees/30 sec); 8 kg 
ball lift to platform at chest height/60 sec; 4 pushups, followed by a 20 sec prone forearm plank, 
4 minutes of vigorous intensity cycling; repeating the circuit above; walking on a treadmill for 4 
minutes; repeating the circuit above; and finishing with 8-10 minutes of cycling at a vigorous 
intensity, to ensure all activity days were 40 minutes in duration. The intensity of the circuit 
ranged from moderate-to-vigorous (50-75% of VO2max) and vigorous-to-maximum (75-100% 
of VO2max). All four exercise sessions were supervised by qualified exercise professionals 
(Certified Exercise Physiologists). Blood glucose was measured every ten minutes for 
participants with T1D. On a subset of study participants, finger prick blood lactate was measured 
every ten minutes to confirm the PA intensity. The exercise collection was terminated based on a 
blood glucose cut-point of 3.5 mmol/l.  
2.3 Data Analysis   
A subset of study participants (n=14) repeated the incremental-to-maximal effort 
treadmill VO2 on two separate occasions. On one occasion, the incremental-to-maximal effort 
treadmill VO2 was completed using the metabolic unit (Fitmate), and on the second occasion the 
identical incremental-to-maximal effort treadmill VO2 protocol was administered using the 
discrete component system.  The results from both systems using the final thirty seconds of each 
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workload were aggregated and compared.  This step was essential to ensure that the measured 
variables of interest from the Fitmate metabolic unit were valid during the light-to-moderate 
intensity 40-50% VO2max continuous exercise and moderate-to-vigorous intensity 51-75% 
VO2max intermittent circuit exercise sessions.  The Fitmate metabolic unit variable outcomes 
were deemed accurate if the variables of interest were not significantly different at the 95% 
confidence level, compared to that of the discrete component system.  
The results of the incremental-to-maximal effort treadmill VO2 protocol were used to 
demarcate the following exercise intensity ranges: light-to-moderate intensity 40-50% VO2max, 
moderate-to-vigorous intensity 51-75% VO2max, vigorous-to-maximum intensity 76-100% 
VO2max (Garber, 2011). These exercise intensities align with the approximate harmonized 
classification of exercise intensities as shown in Table 3.  
Table 3: Shows the approximate classification of exercise intensity using relative and absolute 
methods commonly used in practice. Adopted American College of Sports Medicine (14), 
Howley (173), Swain and Franklin (344), Swain and Leutholtz (346), Swain et al. (347), and the 
US Department of Health and Human Services (370 
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The breath-by-breath data from the Fitmate metabolic unit were also aggregated into 
minute-by-minute values to coincide with the data outputs from the wearable technology, for 
each respective exercise day.  A Paired t-test analysis was performed using SPSS 23.0 was used 
for all the analysis, with a threshold for statistical significance set at p ≤ 0.05 a priori, and the 
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Fitmate metabolic unit was used as the criterion standard for comparison. The comparisons were 
completed for the variables of interest (HR, BR, EE) between devices to determine accuracy and 
reliability.  
Bland-Altman analyses were conducted to determine and illustrate bias using Prism 6. 
The Bland-Altman analysis examines the agreement between the two measurement procedures 
conducted on the same variable at the same time (Altman, 1983). The analyses were performed 
such that the difference of the secondary devices, B, compared to the criterion, A, divided by the 
average of the criterion (Difference B - A / Average). 
 
2.4 Results  
2.4.1 Study Participants’ Characteristics  
Study participants consisted of a total of 25 study participants, 14 males and 11 females, 
18-55 years of age (24.75 ± 7.58), of those, 8 were persons with T1D. The participants with T1D 
had been using an insulin pump for at least six months prior to participating in the study. The 
anthropometric, physical and physiological fitness profiles of all groups and sub-groups are 
reported in Table 4. A significant difference was observed (p=0.045) in Peak exercise HR 
between non-diabetic (ND) females and females with T1D, likely due to the older age of one of 
the female study participants in the T1D group. 
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Table 4: Anthropometric, physical and physiological fitness profiles of both groups. 
 Male   Female  
 ND (n=10) T1D (n=4)  ND (n=7) T1D (n=4) 
Variable Mean ± SD Mean ± SD  Mean ± SD Mean ± SD 
Age (yr) 21 ± 1.6 23 ± 9.2  24 ± 6.0 34 ± 13.5 
Height (cm) 175.3 ± 5.9 180.3 ± 5.9  164.4 ± 3.5 169.5 ± 10.6 
Body Mass (kg) 79.9 ± 7.9 76.5 ± 3.4  64.4 ± 8.3 71.3 ± 9.9 
BMI (kg/m
2
) 26.0 ± 2.2 23.6 ± 2.2  23.8 ± 2.7 24.7 ± 1.5 
Body Fat (%) 19.3 ± 5.1 13.1 ± 6.9  30.1 ± 6.2 31.2 ± 2.7 
Sum of 5 Skinfolds (mm) 53.3 ± 27.1 35.3 ± 10.5  82.1 ± 27.8  79.1 ± 13.8  
Waist Circumference (cm) 84.9 ± 7.9 80.5 ± 3.3  83.2 ± 5.2 87.3 ± 6.6 
Body Composition  
Health Benefit Zone Rating 
 
Very Good 
 
Excellent 
  
Very Good 
 
Very Good 
VO2max (mL·kg
-1
·min
-1
) 49.9 ± 4.3 55.9 ± 6.7  42.0 ± 7.7 38.1 ± 1.9 
Peak HR (bpm) 200 ± 3.7 203 ± 3.6  199 ± 3.9 182 ± 15.7* 
ND represents persons without diabetes and T1D represents study participant with Type One Diabetes 
Health Benefit Zone Rating is a function of the composite body composition score using graduated NIH waist 
circumference, and sum of 5 skinfolds within and across each body mass index category. Very good indicates 
that body composition falls within a range that is generally associated with considerable health benefits. An 
excellent rating indicates that the body composition falls within a range that is generally associated with 
enhanced health benefits. *Significant difference was observed (p=0.045) in Peak exercise HR between non-
diabetic females and females with T1D, due to the older age of one of the female study participants. 
 
2.4.2 Statistical Analysis and Data Interpretation        
 Given the portability of the Fitmate metabolic unit and its need for use during the free-
movement circuit exercise sessions, the researchers had to confirm that the Fitmate metabolic 
unit was in fact accurate. This was accomplished by using a sub-set of the 25 study participants 
(n = 14, male = 7, female = 7) who repeated the identical incremental-to-maximal effort VO2 
protocol on two separate occasions. The data was averaged for the final thirty seconds of each 
two-minute workload. A paired t-test analysis was performed using SPSS 23.0 to compare the 
Fitmate metabolic unit outcomes using the criterion discrete component system. There were no 
significant difference between the two measurement systems for the VO2 max values (p = 0.565). 
The co-relation between the two system for the incremental-to-maximum VO2 values was r = 
0.967 ± 0.03. There were no significant differences for the maximum breathing rate (p = 0.407). 
The co-relation between the two systems for the maximum breathing rate values was, r = 0.921 ± 
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0.04. Statistical analyses were only performed on the grouped data. No statistical analyses were 
conducted for sex differences and between ND and persons with T1D, due to the low number of 
study participants in the sub-groups. The average VO2 max and maximum BR for all study 
participants who repeated the incremental-to-maximum VO2 protocol are represented in Table 5. 
 
Table 5: Discrete Component System versus Metabolic Unit (Fitmate) Accuracy for VO2 
max and maximal Breathing Rate (Mean ± SD) 
                              Max  VO2(mL·kg
-1
·min
-1
)                                Max BR (b/min)                                            
Discrete Component 
System 
Fitmate 
Metabolic Unit 
Discrete Component 
System 
Fitmate 
Metabolic Unit 
Males (n=7) 48.35 ± 4.48 48.34 ± 4.72 57.86 ± 9.63 56.09 ± 10.94 
Females (n=7) 39.60 ± 3.58 38.11 ± 4.34 50.71 ± 11.01 49.72 ± 12.31 
Grouped (n=14) 43.97 ± 5.99 43.23 ± 6.87 54.29 ± 10.61 52.90 ± 11.67 
No significant differences were found 
 
2.4.3 Comparison between wearable technology devices for Energy Expenditure, Heart 
Rate, and Breathing Rate during the incremental-to-maximal effort VO2 protocol  
 The results from the incremental-to-maximal effort VO2 protocol using the Fitmate 
metabolic unit were averaged for every minute to create a common comparison time frame, 
given that the different wearable technology devices collected data at different time frequencies 
(Bioharness every second and Metria every minute). A paired t-test analysis was performed to 
determine if significant differences were observed for the variables of interest (EE, HR, BR) 
between each of the devices at the following intensities; light-to-moderate intensity <50% of 
VO2max (Table 6), moderate-to-vigorous intensity 51-75% of VO2max (Table 7), and vigorous-
to-maximum intensity 76-100% of VO2max (Table 8). No statistical analyses were conducted for 
sex differences and between ND and persons with T1D, due to the low number of study 
participants in the sub-groups. 
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Table 6 contains the EE, HR, and BR data during the light-to-moderate intensity (40-50% 
VO2max) portion of the incremental-to-maximum VO2 protocol using the Fitmate, Metria, and 
Bioharness. For each variable, the number of study participants (N) per group were reported. In 
addition, for each variable the number of data points (n) plus the associated means and standard 
deviations were reported. For each of the variables the statistical analyses were only performed 
on the grouped data. No statistical analyses were conducted for sex differences and between ND 
and persons with T1D, due to the low number of study participants in the sub-groups. Significant 
differences were observed between the Fitmate metabolic unit and the Metria for EE (n = 53, p < 
0.001). The Metria overestimated the EE in the light-to-moderate intensity portion of the the 
incremental-to-maximal effort VO2 protocol. Significant differences were also observed between 
the Fitmate metabolic unit and Bioharness for HR (n = 76, p < 0.001) and BR (n = 73, p = 
0.004). The Bioharness underestimated both the BR and HR in the light-to-moderate intensity 
portion. 
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Table 6: Comparison of Energy Expenditure, Heart Rate, and Breathing Rate between devices during the light-to-moderate 
intensity portion of the incremental-maximum effort VO2 protocol (Mean ± SD) 
   Energy Expenditure                       Heart Rate                            Breathing Rate 
N n Fitmate N Metria N n Polar Bioharness N n Fitmate  Bioharness 
Males  10 23 7.32 ± 1.99 6 7.72 ± 2.48 10 34 111.24 ± 14.07 109.36 ± 15.84 10 34 22.87 ± 5.71 22.07 ± 7.67 
Females 6 12 5.04 ± 1.05 4 5.28 ± 1.38 6 21 123.16 ± 12.11   124.14 ± 15.79 6 18 28.22 ± 5.50 22.59 ± 6.55 
                    
Persons 
with 
Diabetes 
                  
   Males 2 8 6.07 ± 1.57 2 7.43 ± 2.81 2 8 119.08 ± 14.08 114.77 ± 12.00 2 8 20.46 ± 3.49 26.92 ±13.22 
   
Females 
3 10 5.99 ± 1.85 2 6.35 ± 2.40 3 13 135.11 ± 3.00 117.89 ± 17.64 3 13 26.34 ± 6.43 21.79 ± 5.87 
                    
Grouped 21 53 6.38 ± 2.01 6 6.71 ± 2.41** 10 76 116.57 ± 14.43 115.97 ± 17.38** 10 73 25.14 ± 6.19    22.29 ± 7.17* 
** Denotes a significant difference in Energy Expenditure (p < 0.001), Heart Rate (p < 0.001), and * for Breathing Rate (p < 0.05). N denotes the 
number of study participants per group. n denotes the number of data points used in the statistical analyses.  
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Table 7 contains the EE, HR, and BR data during the moderate-to-vigorous (51-75% 
VO2max) intensity portion of the incremental-to-maximum VO2 protocol using the Fitmate, 
Metria, and Bioharness. For each variable, the number of study participants (N) per group are 
reported. In addition, for each variable the number of data points (n) and the associated means 
and standard deviations are reported. For each of the variables the statistical analyses were only 
performed on the grouped data. No statistical analyses were conducted for sex differences and 
between ND and persons with T1D, due to the low number of study participants in the sub-
groups. Significant differences were observed between the Fitmate metabolic unit and Metria for 
EE (n = 37, p < 0.001). Significant differences were also observed between the Fitmate 
metabolic unit and Bioharness for BR (n = 64, p < 0.001) and HR (n = 64, p < 0.001). 
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Table 7: Comparison of Energy Expenditure, Heart Rate, and Breathing Rate between devices during the moderate-to-
vigorous intensity portion of the incremental-maximum effort VO2 protocol (Mean ± SD)  
   Energy Expenditure           Heart Rate              Breathing Rate 
N n Fitmate N Metria N n Polar Bioharness N n Fitmate Bioharness 
Males  10 17 12.58 ± 2.34 6 13.27 ± 2.07 10 33 155 ± 14 150 ± 18 10 33 40.58 ± 18.29 29.14 ± 7.54 
Females 6 11 8.12 ± 1.17 4 8.78 ± 1.30 6 22 154 ± 14 150 ± 21 6 22 36.94 ± 4.74 30.12 ± 6.44 
                   
Persons 
with 
Diabetes 
                 
   Males 2 4 11.96 ± 2.73 2 13.53 ± 0.84 2 4 151 ± 11 147 ± 11 2 4 25.22 ± 2.75 18.72 ± 5.00 
   Females 3 5 8.52 ± 1.16 2 7.78 ± 1.33 3 8 149 ± 17 153 ± 28 3 8 33.74 ± 4.45 32.45 ± 5.95 
                   
Grouped 21 37 10.68 ± 2.91 14 11.32 ± 2.86** 21 67 155 ± 14 150 ± 19** 21 67 39.04 ± 14.27 29.55 ± 7.06** 
**Denotes a significant difference in Energy Expenditure (p < 0.001), Heart Rate (p < 0.001), and Breathing Rate (p < 0.001). N denotes the 
number of study participants per group. n denotes the number of data points used in the statistical analyses.  
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Table 8 contains the EE, HR, and BR data during the vigorous-to-maximal (76-100% VO2max) 
intensity portion of the incremental-to-maximum VO2 protocol using the Fitmate, Metria, and 
Bioharness. For each variable, the number of study participants (N) per group are reported. In 
addition, for each variable the number of data points (n) and the associated means and standard 
deviations are reported. For each of the variables the statistical analyses were only performed on 
the grouped data. No statistical analyses were conducted for sex differences and between ND and 
persons with T1D, due to the low number of study participants in the sub-groups.  Significant 
differences were observed between the Fitmate metabolic unit and Metria for EE (n = 191, p < 
0.001) and the Fitmate metabolic unit and Bioharness for BR (n = 267, p < 0.001) and HR (n = 
267, p =0.038). 
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Table 8: Comparison of Energy Expenditure, Heart Rate, and Breathing Rate between devices during the vigorous-to-
maximum intensity portion of the incremental-maximum effort VO2 protocol (Mean ± SD)  
   Energy Expenditure           Heart Rate              Breathing Rate 
N n Fitmate N Metria N n Polar Bioharness N n Fitmate Bioharness 
Males  10 86 15.82 ± 3.69 6 13.50 ± 2.64 10 124 179 ± 13 179 ± 14 10 124 49.49 ± 21.30 37.22 ± 7.85 
Females 6 49 10.82 ± 2.28 4 9.78 ± 1.78 6 95 174 ± 17 178 ± 15 6 95 46.54 ± 8.16 41.05 ± 7.00 
                   
Persons 
with 
Diabetes 
                 
   Males 2 24 18.02 ± 5.82 2 14.58 ± 2.65 2 12 186 ± 12 185 ± 11 2 12 42.59 ± 10.74 33.81 ± 11.07 
   Females 3 32 11.01 ± 1.95 2 9.28 ± 1.92 3 36 171 ± 14 170 ± 18 3 36 42.89 ± 4.05 41.37 ± 4.47 
                   
Grouped 21 191 13.70 ± 4.02 14 11.92 ± 2.95** 21 267 177 ± 15 178 ± 14 21 267 48.18 ± 16.80 38.93 ± 7.72** 
**Denotes a significant difference in Energy Expenditure, and Breathing Rate (p < 0.001). N denotes the number of study participants per group. n 
denotes the number of data points used in the statistical analyses.
37 
 
Bland-Altman Analysis 
Bland-Altman analyses were conducted to determine and illustrate bias using GraphPad Prism 6. 
The Bland-Altman analysis examines the agreement between the two measurement procedures 
conducted on the same variable at the same time (Altman, 1983). The analyses were performed 
such that the difference of the secondary devices, B, compared to the criterion, A, divided by the 
average of the two devices [Difference (B – A) / Average 
𝐵+𝐴
2
)].The results for EE during the 
light-to-moderate intensity), moderate-to-vigorous intensity (51-75% VO2max), vigorous-to-
maximal intensity (76-100% VO2max), portion of incremental-maximum effort VO2 protocol are 
displayed in Figures 3a, 3b, 3c, respectively. The results for HR during the light-to-moderate 
intensity), moderate-to-vigorous intensity (51-75% VO2max), vigorous-to-maximal intensity 
(76-100% VO2max), portion of incremental-maximum effort VO2 protocol are displayed in 
Figures 4a, 4b, 4c, respectively. The results for BR during the light-to-moderate intensity), 
moderate-to-vigorous intensity (51-75% VO2max), vigorous-to-maximal intensity (76-100% 
VO2max), portion of incremental-maximum effort VO2 protocol are displayed in Figures 5a, 5b, 
5c, respectively.  
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Bland-Altman plots for the Fitmate versus Metria during the light-to-moderate intensity 
(40-50% VO2max), moderate-to-vigorous intensity (51-75% VO2max), vigorous-to-
maximal intensity (76-100% VO2max), portions of incremental-maximum effort VO2 
protocol for Energy Expenditure 
 
Figure 3a contains the results from the Bland-Altman plot for the Fitmate metabolic 
versus the Metria during the light-to-moderate intensity portion of the incremental-maximum 
effort VO2 protocol for EE. The results demonstrate that the Metria has a bias of 0.28 ± 1.62 
kcals · minute
-1
 with 95% limits of agreement from -2.91 – 3.46 kcals · minute-1. This indicates 
that on average the Metria overestimates the EE by 0.28 kcals · minute
-1
.  
 
Figure 3b contains the results from the Bland-Altman plot for the Fitmate metabolic unit 
versus the Metria during the moderate-to-vigorous intensity portion of the incremental-to-
maximum effort VO2 protocol for EE. The results demonstrate that the Metria has a bias of 0.64 
± 1.65 kcals · minute
-1
 with 95% limits of agreement from -2.59 – 3.87 kcals · minute-1. This 
indicates that on average the Metria generally overestimates the EE by 0.64 kcals per minute.  
 
Figure 3c contains the results from the Bland-Altman plot for the Fitmate metabolic unit 
versus the Metria during the vigorous-to-maximal intensity portion of the incremental-maximum 
effort VO2 protocol for EE. The results demonstrate that the Metria has a bias of -1.78 ± 2.77 
with 95% limits of agreement from -7.22 – 3.65. This indicates that on average the Metria 
generally underestimates the EE by 1.78 kcals per minute.  
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Bland-Altman plots for the Polar versus Bioharness during the light-to-moderate intensity 
(40-50% VO2max), moderate-to-vigorous intensity (51-75% VO2max), vigorous-to-
maximal intensity (76-100% VO2max), portions of incremental-maximum effort VO2 
protocol for Heart Rate 
 
Figure 4a contains the results from the Bland-Altman plot for the Polar versus the 
Bioharness during the light-to-moderate intensity portion of the incremental-maximum effort 
VO2 protocol for HR. The results demonstrate that the Bioharness has a bias of -0.60 ± 7.86 bpm 
with 95% limits of agreement from -16.01 – 14.82 bpm. This indicates that on average the 
Bioharness generally underestimates the HR by 0.60 bpm.  
 
Figure 4b contains the results from the Bland-Altman plot for the Polar versus the 
Bioharness during the moderate-to-vigorous intensity portion of the incremental-maximum effort 
VO2 protocol for HR. The results demonstrate that the Bioharness has a bias of -4.73 ± 11.07 
bpm with 95% limits of agreement from -26.42 – 16.96 bpm. This indicates that on average the 
Bioharness generally underestimates the HR by -4.73 bpm.  
 
Figure 4c contains the results from the Bland-Altman plot for the Fitmate metabolic unit 
versus the Bioharness during the vigorous-to-maximal intensity portion of the incremental-
maximum effort VO2 protocol for HR. The results demonstrate that the Bioharness has a bias of 
1.45 ± 11.56 with 95% limits of agreement from -21.20 – 24.11. This indicates that on average 
the Bioharness generally overestimates the HR by 1.45 bpm.  
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Bland-Altman plots for the Polar versus Bioharness during the light-to-moderate intensity 
(40-50% VO2max), moderate-to-vigorous intensity (51-75% VO2max), vigorous-to-
maximal intensity (76-100% VO2max), portions of incremental-maximum effort VO2 
protocol for Breathing Rate 
 
Figure 5a contains the results from the Bland-Altman plot for the Fitmate metabolic 
versus the Bioharness during the light-to-moderate intensity portion of the incremental-
maximum effort VO2 protocol for BR. The results demonstrate that the Bioharness has a bias of -
2.85 ± 7.765 breaths/min with 95% limits of agreement from -18.04 – 12.34 breaths/min. This 
indicates that on average the Bioharness generally underestimates the BR by 2.85 breaths/min.  
 
Figure 5b contains the results from the Bland-Altman plot for the Fitmate metabolic unit 
versus the Bioharness during the moderate-to-vigorous intensity portion of the incremental-
maximum effort VO2 protocol for BR. The results demonstrate that the Bioharness has a bias of -
9.49 ± 11.97 with 95% limits of agreement from -32.96 – 13.98. This indicates that on average 
the Bioharness generally underestimates the BR by 9.49 breaths/minute.  
 
Figure 5c contains the results from the Bland-Altman plot for the Fitmate metabolic unit 
versus the Bioharness during the vigorous-to-maximal intensity portion of the incremental-to-
maximum effort VO2 protocol for BR. The results demonstrate that the Bioharness has a bias of -
5.61 ± 8.34 breaths/min with 95% limits of agreement from -21.96 – 10.73 breaths/min. This 
indicates that on average the Bioharness generally underestimates the BR by 5.61 
breaths/minute.  
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A paired t-test analysis was performed (Table 9) for total EE reported from each of the consumer 
devices versus the Fitmate metabolic unit, in order to examine the accuracy of the Garmin 
VivoFit 2 and the Mio Fuse. No significant differences were observed for either of the devices, 
compared to the Fitmate (p < 0.05). 
 
Table 9: Accuracy of Consumer Based Wearable Technology for Total Energy 
Expenditure during the incremental-to-maximum effort VO2 protocol (Mean ± SD) 
 
 
 
No significant differences were observed for either of the devices compared to Fitmate (p <0.05). N 
denotes the number of study participants per group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  N Fitmate Garmin N Fitmate Mio 
Grouped   4 278.07 ± 77.39 327.00 ± 139.38 4 212.42 ± 102.25 381.00 ± 150.08 
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2.4.4 Circuit Exercise Data 
 
To determine whether or not the select devices were accurate during moderate-to-vigorous 
intensity free motion PA, the results from the 40-minute circuit were examined.  The data was 
averaged for every minute to create a common time variable, as different devices collected data 
at different frequencies (Bioharness every second and Metria every minute). For each variable, 
the number of study participants (N) per group are reported. In addition, for each variable the 
number of data points (n) plus the associated means and standard deviations are reported in 
Table 10. There were significant differences in EE (p < 0.001), HR (p<0.001), and BR (p = 
0.001). In addition, all variables were underestimated relative to the criterion standard 
measurements. Varying sample sizes for EE derived from the Metria were due to equipment 
malfunction. Reliability was also investigated by examining the data of those individuals who 
repeated the circuit under similar conditions on a separate day. The descriptive statistics (Mean ± 
SD), results from the paired t-test analysis, unit difference, and percent difference are contained 
in Table 10, 11, and 12 for EE, HR, and BR, respectively.  
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Table 10 contains the EE, HR, and BR data during the first circuit trial using the Fitmate 
metabolic unit, Metria, and Bioharness. For each variable, the number of study participants (N) 
per group are reported. In addition, for each variable the number of data points (n) and the 
associated means and standard deviations are reported. For each of the variables the statistical 
analyses were only performed on the grouped data. No statistical analyses were conducted for 
sex differences and between ND and persons with T1D, due to the low number of study 
participants in the sub-groups.  Significant differences were observed between the Fitmate 
metabolic unit and Metria for EE (n = 604, p < 0.001), HR (n = 873, p < 0.001) and Bioharness 
for BR (n = 872, p = 0.001).  
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Table 10: Energy Expenditure, Heart Rate, and Breathing Rate during the first circuit trial (Mean ± SD) 
   Energy Expenditure  Heart Rate  Breathing Rate 
N n Fitmate N Metria N n Polar Bioharness N n Fitmate  Bioharness 
Males  10 229 9.26 ± 2.42 6 7.01 ± 3.65 10 387 146 ± 22 147 ± 21 10 388 33.02 ± 7.17 27.97 ± 6.70 
Females 7 157 6.45 ± 1.32 4 5.33 ± 6.28 7 271 160 ± 21 155 ± 22 7 271 35.58 ± 7.38 29.24 ± 7.61 
                     
Persons 
with 
Diabetes 
                  
   Males 3 120 9.38 ± 1.60 4 6.72 ± 1.69 3 116 164 ± 21 157 ± 22 3 116 33.63 ± 7.33 27.25 ± 6.49 
   Females 3 98 7.43 ± 1.48 3 5.44 ± 1.62 3 98 145 ± 20 146 ± 22 3 98 38.95 ± 6.02 31.87 ± 6.46 
                     
Grouped 23 604 8.32 ± 2.34 17 6.25 ± 2.56** 23 872 153 ± 23 151 ± 22** 23 873 34.46 ± 7.38 28.63 ± 7.05* 
**Denotes a significant difference in Energy Expenditure, and Heart Rate (p < 0.001). *Denotes a significant difference in Breathing Rate (p = 
0.001). N denotes the number of study participants per group. n denotes the number of data points used in the statistical analyses. 
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Table 11 contains the test-retest reliability data of the study participants who repeated the 
circuit on two separate occasions, using the Fitmate metabolic and Metria for Energy 
Expenditure. The number of study participants (N) per group are reported. In addition, the 
number of data points (n) plus the associated mean and standard deviation are reported. The 
statistical analyses were only performed on the grouped data. During circuit trials 1 and 2 there 
was a significant difference between the Fitmate and Metria for EE. However, there were no 
significant differences between circuit trials 1 and 2 for the kcals · minute
-1
using the Fitmate 
metabolic unit. Similarly, there were no significant differences between circuit trials 1 and 2 for 
the kcals · minute
-1
 using the Metria. The unit difference for EE was calculated for each device 
by subtracting the Circuit Trial 1 value from the Circuit Trial 2 value. Percent difference was 
calculated for circuit trials 1 and 2 for the Fitmate metabolic unit. Percent difference was 
calculated for circuit trials 1 and 2 for the Bioharness. No statistical analyses were conducted for 
sex differences and between ND and persons with T1D, due to the low number of study 
participants in the sub-groups. 
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Table 11: Test-retest Energy Expenditure data from study participants who repeated the circuit exercise session on two 
separate occasions (Mean ± SD) 
No significant differences were observed for the Metria compared to Fitmate (p < 0.05).  
“-” Denotes no data 
 
                    Energy Expenditure 
                         Circuit Trial 1                       Circuit Trial 2                          Unit Difference (C1 – C2)                           % Difference (C1 & C2)   
  N n Fitmate Metria Fitmate Metria Fitmate Metria Fitmate Metria 
Males 2 0 8.700 ± 1.26 - 8.79 ± 1.20 - -0.09 ± 0.75 - -1.41 % ± 9.06 - 
Females  3 0 6.57 ± 1.40 - 6.25 ± 1.00 - 0.32 ± 1.05 - 2.54 % ± 19.99 - 
                  
Persons 
with 
Diabetes 
                
   Males  4 21 9.21 ± 1.44 6.84 ± 1.36 9.45 ± 1.91 6.63 ± 1.94 -0.24 ± 1.56 0.21 ± 1.54 -3.07 % ± 18.19 2.82 % ± 22.07 
   Females  2 14 7.47 ± 1.44 5.15 ± 1.23 7.71 ± 1.38 5.38 ± 0.96 -0.24 ± 0.85 -0.22 ± 1.41 -4.01 % ± 10.91 9.18 % ± 29.12 
                  
Grouped  11 35 7.99 ± 1.76 6.25 ± 1.53* 8.07 ± 1.90 6.20 ± 1.71* -0.41 ± 2.11 0.60 ± 3.49 - 1.29 % ± 15.94 -1.98 % ± 25.42 
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Table 12 contains the test-retest reliability data of the study participants who repeated the 
circuit on two separate occasions, using the Fitmate metabolic and Bioharness for Heart Rate. 
The number of study participants (N) per group were reported. In addition, the number of data 
points (n) plus the associated mean and standard deviation were reported. The statistical analyses 
were only performed on the grouped data only. During circuit trial 1 there was a significant 
difference between the Fitmate and Bioharness for HR. There was a significant difference 
between circuit trials 1 and 2 for the HR using the Fitmate metabolic unit. There was no 
significant difference between circuit trials 1 and 2 using the Bioharness. The unit difference for 
HR was calculated for each device by subtracting the Circuit Trial 1 value from the Circuit Trial 
2 value. Percent difference was calculated for circuit trials 1 and 2 for the Fitmate metabolic unit. 
Percent difference was calculated for circuit trials 1 and 2 for the Bioharness. No statistical 
analyses were conducted for sex differences and between ND and persons with T1D, due to the 
low number of study participants in the sub-groups. 
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Table 12: Test-retest Heart Rate data from study participants who repeated the circuit exercise session on two separate 
occasions (Mean ± SD) 
*Denotes a significant difference in Heart Rate (p < 0.05), between the test-retest for the Fitmate. N denotes the number of study participants per 
group. n denotes the number of data points used in the statistical analyses. 
 
 
                    Heart Rate 
                         Circuit Trial 1                       Circuit Trial 2                Unit Difference (C1 – C2)                       % Difference (C1 &  C2)   
  N n Polar Bioharness Polar Bioharness Polar Bioharness Polar Bioharness 
Males 2 14 135 ± 17 136 ± 17 127 ± 16 127 ± 16 8 ± 4 9 ± 3 6 % ± 2 7 % ± 2 
Females  3 20 156 ± 20 144 ± 21 154 ± 17 155 ± 18 2 ± 19 -12 ± 16 1 % ± 13 -9 % ± 13 
                  
Persons 
with 
Diabetes 
                
   Males  4 21 162 ± 21 155 ± 22 152 ± 23 154 ± 23 10 ± 15 -7 ± 40 6 % ± 10 1 % ± 8 
  Females  2 14 145 ± 20 148 ± 19 146 ± 19 142 ± 21 -1 ± 7 6 ± 7 -1 % ± 5 4 % ± 5 
                  
Grouped  11 69 152 ± 22 146 ± 21* 147 ± 22 14 ± 22 5 ± 14* -3 ± 25 3 % ± 9* 0 % ± 10.35 
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Table 13 contains the test-retest reliability data of the study participants who repeated the 
circuit on two separate occasions, using the Fitmate metabolic and Bioharness for BR. The 
number of study participants (N) per group were reported. In addition, the number of data points 
(n) plus the associated mean and standard deviation were reported. The statistical analyses were 
only performed on the grouped data. During circuit trials 1 and 2 there was a significant 
difference between the Fitmate and Bioharness for BR. However, there was no significant 
difference between circuit trials 1 and 2 using the Fitmate metabolic unit for BR. Similarly, there 
was no significant difference between circuit trials 1 and 2 using the Bioharness for BR. The unit 
difference for BR was calculated for each device by subtracting the Circuit Trial 1 value from the 
Circuit Trial 2 value. Percent difference was calculated for circuit trials 1 and 2 for the Fitmate 
metabolic unit. Percent difference was calculated for circuit trials 1 and 2 for the Bioharness. No 
statistical analyses were conducted for sex differences and between ND and persons with T1D, 
due to the low number of study participants in the sub-groups. 
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Table 13: Test-retest Breathing Rate data from study participants who repeated the circuit exercise session on two separate 
occasions (Mean ± SD) 
**Denotes a significant difference in BR (p < 0.001), for circuit trial 1 between the Fitmate metabolic unit and Bioharness. **Denotes a significant 
difference in BR (p < 0.001), for circuit trial 2 between the Fitmate metabolic unit and Bioharness. N denotes the number of study participants per 
group. n denotes the number of data points used in the statistical analyses. 
                   Breathing Rate 
                         Circuit Trial 1                Circuit Trial 2                             Unit Difference (C1 – C2)                        % Difference (C1 &  C2)   
  N n Fitmate Bioharness Fitmate Bioharness Fitmate Bioharness Fitmate Bioharness 
Males 2 14 30.98 ± 6.27 26.64 ± 5.83 28.50 ± 7.47 25.77 ± 6.43 2.47 ± 5.85 0.87 ± 6.10 6.42 % ± 22.13 0.38 % ± 26.19 
Females  3 20 35.19 ± 5.67 28.90 ± 5.83 34.44 ± 6.27 30.00 ± 5.77 0.75 ± 4.51 -1.10 ± 3.44 1.62 % ± 12.51 - 2.09 %  ± 11.89 
                  
Persons 
with 
Diabetes 
                
   Males  4 21 32.86 ± 7.55 26.82 ± 5.26 31.53 ± 5.56 27.68 ± 5.31 1.33 ± 5.21 -1.95 ± 8.77 1.66 % ± 16.63 -2.09 % ± 11.80 
 Females  2 14 38.012 ± 5.21 32.45 ± 5.06 39.70 ± 4.77 31.61 ± 4.95 -0.78 ± 3.82 0.85 ± 4.10 -2.61 % ± 10.59 2.09 % ± 11.26 
                  
Grouped  11 69 34.38 ± 6.79 28.56 ± 5.82** 33.75 ± 7.12 28.48 ± 6.13** 0.96 ± 4.91 -0.60 ±  6.23 1.75 % ± 15.77 -1.62 % ± 15.97 
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Bland-Altman Analysis 
Bland-Altman analyses were conducted to determine and illustrate bias using GraphPad Prism 6. 
The Bland-Altman analysis examines the agreement between the two measurement procedures 
conducted on the same variable at the same time (Altman, 1983). The analyses were performed 
such that the difference of the secondary devices, B, compared to the criterion, A, divided by the 
average of the two devices [Difference (B – A) / Average 
𝐵+𝐴
2
)]. The results for EE, HR, BR 
during the 40-minute circuit are displayed in Figures 6, 7, 8, respectively.  
Figure 6 contains the results from the Bland-Altman plot for the Fitmate metabolic unit 
versus the Metria during the Circuit Trial 1 for EE. The results demonstrate that the Metria has a 
bias of -2.49 ± 2.34 with 95% limits of agreement from -7.07 – 2.10. This indicates that on 
average the Metria generally underestimates the EE by 2.49 kcals.  
 
Figure 6: Bland-Altman plot for the Fitmate metabolic unit versus Metria during the 40-
minute circuit for Energy Expenditure 
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Figure 7 contains the results from the Bland-Altman plot for the Fitmate metabolic unit 
versus the Bioharness during the Circuit for HR. The results demonstrate that the Bioharness has 
a bias of -2.01 ± 13.04 bpm with 95% limits of agreement from -27.57 – 23.56 bpm. This 
indicates that on average the Bioharness generally underestimates the HR by 2.01 bpm.  
 
Figure 7: Bland-Altman plot for the Fitmate metabolic unit versus Bioharness during the 
40-minute circuit for Heart Rate 
 
 
 
 
 
 
 
  
56 
 
 Figure 8 contains the results from the Bland-Altman plot for the Fitmate metabolic unit 
versus the Bioharness during the Circuit for BR. The results demonstrate that the Bioharness has 
a bias of -4.96 ± 4.91 breaths/min with 95% limits of agreement from -14.58 – 4.67 breath/min. 
This indicates that on average the Bioharness generally underestimates the BR by 4.96 
breaths/min. 
Figure 8: Bland-Altman plot for the Fitmate versus Bioharness during the 40-minute 
circuit for Breathing Rate 
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In addition to the Metria and Bioharness, the Garmin VivoFit 2 and Mio Fuse, were also 
examined during the circuit free motion activity. The accuracy of the total EE reported from 
these devices was determined using a paired t-test analysis. The results are summarized in Table 
14, along with the Mean ± SD for the variables of interest (EE). No significant differences were 
observed for either of the devices, compared to the Fitmate metabolic unit (p < 0.05). The 
statistical analyses should be interpreted with caution given the small sample sizes.  
 
Table 14: Accuracy of Consumer Based Wearable Technology for Energy Expenditure 
during Circuit (Mean ± SD) 
 
 
 
No significant differences were observed for either of the devices compared to Fitmate (p <0.05). 
 
 
  
  N Fitmate Garmin N Fitmate Mio 
Grouped   7 343.38 ± 50.81 310.43 ± 201.80 5 297.92 ± 56.00 431.00 ± 234.29 
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2.4.5 Continuous Light-to-Moderate Intensity Treadmill Activity 
The accuracy of the wearable technology was examined during the 40-minutes of continuous 
light-to-moderate intensity treadmill activity. The data was averaged for every minute to create a 
common time variable as different devices collected data at different frequencies. The results of 
the paired t-test analysis, as well as Mean ± SD for the variables of interest (EE, HR, BR), can be 
found below in Table 15. There was a significant difference in EE (p < 0.001) and HR (p < 
0.001). Varying sample sizes in the EE from the Metria are due to equipment malfunction. 
Reliability was also investigated by examining the data of those individuals who repeated the 
continuous light-to-moderate intensity treadmill activity under similar conditions. Note that 
persons with T1D did not repeat the continuous light-to-moderate intensity protocol for safety 
purposes. The descriptive statistics (Mean ± SD), results from the paired t-test analysis, unit 
difference, and percent difference are contained in Table 16, 17, and 18 for EE, HR, and BR, 
respectively.   
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Table 15 contains the EE, HR, and BR data during the continuous light intensity treadmill 
activity using the Fitmate, Metria, and Bioharness. For each variable, the number of study 
participants (N) per group were reported. In addition, for each variable the number of data points 
(n) plus the associated mean and standard deviation were reported. For each of the variables the 
statistical analyses were performed on the grouped data. No statistical analyses were conducted 
for sex differences and between ND and persons with T1D, due to the low number of study 
participants in the sub-groups. Significant differences were observed between the Fitmate 
metabolic unit and Metria for EE (n = 670, p < 0.001) and Bioharness for HR (n = 974, p < 
0.001). 
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Table 15: Initial trial for the continuous light-to-moderate intensity activity for Energy Expenditure, Heart Rate, and 
Breathing Rate (Mean ± SD) 
   Energy Expenditure           Heart Rate              Breathing Rate 
N n Fitmate N Metria N n Polar Bioharness N n Fitmate Bioharness 
Males  10 233 8.76 ± 1.25 6 8.17 ± 1.91 10 388 127 ± 11 128 ± 14 10 388 26.82 ± 5.48 27.07 ± 5.78 
Females 7 160 6.23 ± 0.77 4 6.01 ± 1.42 7 279 137 ± 11 140 ± 19 7 279 28.98 ± 6.59 28.58 ± 7.16 
    
 
 
 
  
  
  
  
Persons 
with 
Diabetes 
  
 
 
 
  
  
  
  
   Males 4 159 8.52 ± 2.55 4 8.19 ± 2.16 4 159 131 ± 15 130 ± 19 4 159 24.50 ± 6.49 25.43 ± 6.62 
   Females 3 118 6.45 ± 1.21 3 5.27 ± 1.81 3 148 113 ± 16 114 ± 16 3 148 31.77 ± 4.27 30.41 ± 3.96 
    
 
 
 
  
  
  
  
Grouped 24 670 7.68 ± 1.87 17 7.15 ± 2.13* 24 974 129 ± 15 130 ± 18* 24 974 27.68 ± 6.26 27.65 ± 6.36 
*Denotes a significant difference in EE (p < 0.001) and HR (p < 0.001). N denotes the number of study participants per group. n denotes the 
number of data points used in the statistical analyses. 
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Table 16 contains the test-retest data of the study participants who repeated the light-to-
moderate intensity activity on two separate occasions, using the Fitmate metabolic and Metria for 
EE. The number of study participants (N) per group are reported. In addition, the number of data 
points (n) plus the associated mean and standard deviation are reported. The statistical analyses 
were only performed on the grouped data. During light trials 1 and 2 there was a significant 
difference with the Fitmate metabolic unit for EE. However, there were no significant 
differences between light trials 1 and 2 for the kilocalories/min using the Metria. The unit 
difference for EE was calculated for each device by subtracting the Light Trial 1 value from the 
Light Trial 2 value. Percent difference was calculated for light trials 1 and 2 for the Fitmate 
metabolic unit. Percent difference was calculated for light trials 1 and 2 for the Metria. No 
statistical analyses were conducted for sex differences and between ND and persons with T1D, 
due to the low number of study participants in the sub-groups. 
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Table 16: Test-retest Energy Expenditure data from study participants who repeated continuous light-to-moderate intensity 
activity session on two separate occasions (Mean ± SD) 
*Denotes a significant difference in the Fitmate metabolic unit for EE (p < 0.001) between light trials 1 and 2 using. N denotes the number of 
study participants per group. n denotes the number of data points used in the statistical analysis. 
                    Energy Expenditure 
                  Light-Moderate  
                  Intensity Trial 1 
             Light-Moderate 
             Intensity Trial 2                    Unit Difference (L1 – L2)                       % Difference (L1 &  L2)   
  N n Fitmate Metria Fitmate Metria Fitmate Metria Fitmate Metria 
Males 8 233 8.66 ± 1.20 8.18 ± 1.91 9.01 ± 1.35 8.12 ± 1.87 -0.35 ± 1.32 0.06 ± 1.61  -5.27 % ± 17.69 -3.63 % ± 22.13 
Females  4 157 6.41 ± 0.74 6.03 ± 1.42 7.21 ± 1.64 6.27 ± 1.42 -0.80 ± 1.46 -0.24 ± 1.19
+
 -12.99 % ± 24.07 -6.95 % ± 26.40 
                  
Grouped  12 390 7.91 ± 1.51 7.31 ± 2.02       8.41 ± 1.68 7.38 ± 1.87     -0.51 ± 1.38*   -0.06 ± 1.46 -7.88 %  ± 20.38* -3.63 % ± 22.13 
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Table 17 contains the test-retest data of the study participants who repeated the light-to-
moderate intensity activity on two separate occasions, using the Fitmate metabolic and 
Bioharness for Heart Rate. The number of study participants (N) per group are reported. In 
addition, the number of data points (n) plus the associated means and standard deviations are 
reported. The statistical analyses were only performed on the grouped data. During light-to-
moderate intensity continuous trials 1 and 2 there was no significant difference with the Fitmate 
metabolic unit for HR. Similarly, during the light-to-moderate intensity continuous trials 1 and 2 
there was no significant difference with the Bioharness for HR. However, there was a significant 
difference between light trials 1 and 2 for the HR using the Fitmate metabolic unit. There was 
also a significant difference between light trials 1 and 2 for the HR using the Bioharness. The 
unit difference for HR was calculated for each device by subtracting the Light Trial 1 value from 
the Light Trial 2 value. Percent difference was calculated for light trials 1 and 2 for the Fitmate 
metabolic unit. Percent difference was calculated for light trials 1 and 2 for the Bioharness. No 
statistical analyses were conducted for sex differences and between ND and persons with T1D, 
due to the low number of study participants in the sub-groups. 
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 Table 17: Test-retest Heart Rate data from study participants who repeated continuous light-to-moderate intensity activity 
session on two separate occasions (Mean ± SD) 
*Denotes a significant difference in the Fitmate metabolic unit for EE (p < 0.001) between light trials 1 and 2 using. N denotes the number of 
study participants per group. n denotes the number of data points used in the statistical analysis
                   Heart Rate 
                      Light-Moderate Intensity Trial 1    Light-Moderate Intensity Trial 2               Unit Difference (L1 – L2)                % Difference (L1 &  L2)   
  N n Polar Bioharness          Polar    Bioharness Polar Bioharness Polar Bioharness 
Males 8 310 129 ± 11 128 ± 13 129  ± 13 132 ± 17 2 ± 11 -4 ± 20 1 % ± 8 -4 % ± 16 
Females  4 157 139  ± 13 136 ± 15 132  ± 15 134 ± 13 8 ± 10 2 ± 12 5 % ± 7 1 % ± 10 
            
Grouped  12 467 132  ± 13 131 ± 14 129 ± 13* 133 ± 16* 4 ± 11* -2 ± 18* 2 % ± 8* -2 % ± 14* 
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Table 18 contains the test-retest data of the study participants who repeated the light-to-
moderate intensity activity on two separate occasions, using the Fitmate metabolic unit and 
Bioharness for BR. The number of study participants (N) per group are reported. In addition, the 
number of data points (n) plus the associated mean and standard deviation are reported. The 
statistical analyses were only performed on the grouped data. Between light-to-moderate 
intensity trials 1 and 2 there was a significant difference with the Bioharness for BR. However, 
there was no significant difference between light-to-moderate trials 1 and 2 for the BR using the 
Fitmate metabolic unit. The unit difference for BR was calculated for each device by subtracting 
the light-to-moderate intensity Trial 1 value from the Light-to-moderate intensity Trial 2 value. 
Percent difference was calculated for light-to-moderate intensity trials 1 and 2 for the Fitmate 
metabolic unit. Percent difference was calculated for light trials 1 and 2 for the Bioharness. No 
statistical analyses were conducted for sex differences and between ND and persons with T1D, 
due to the low number of study participants in the sub-groups. 
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Table 18: Test-retest Breathing Rate data from study participants who repeated continuous light-to-moderate intensity 
activity session on two separate occasions (Mean ± SD) 
*Denotes a significant difference in the Bioharness metabolic unit for BR (p < 0.001) between light-to-moderate trials 1 and 2 using. N denotes the 
number of study participants per group. n denotes the number of data points used in the statistical analysis.
                    Breathing Rate 
                      Light-Moderate  
                      Intensity Trial 1 
            Light-Moderate  
            Intensity Trial 2                      Unit Difference (L1 – L2)                % Difference (L1 &  L2)   
  N n Fitmate Bioharness Fitmate Bioharness Fitmate Bioharness Fitmate Bioharness 
Males 8 310 27.94 ± 4.87 28.00 ± 5.79 27.92 ± 4.28 27.54 ± 5.09 -0.02 ± 4.94 0.53 ± 6.43 -1.72 % ± 17.12 -0.89 % ± 22.87 
Females  4 157 29.09 ± 8.24 28.02 ± 8.84 29.27 ± 6.63 31.27 ± 5.28 -0.18 ± 6.45 -3.24 ± 8.79 -6.62 % ± 33.59 -24.54 % ± 51.36 
                  
Grouped  12  467  28.33 ± 6.23 28.01 ± 6.96 28.38 ± 5.23 28.80 ± 5.44*    -0.06 ± 5.49 -0.74 ± 7.52* - 3.37 % ± 24.06 - 8.88 % ± 36.85* 
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Bland-Altman Analysis 
Bland-Altman analyses were conducted to determine and illustrate bias using GraphPad Prism 6. 
The Bland-Altman analysis examines the agreement between the two measurement procedures 
conducted on the same variable at the same time (Altman, 1983). The analyses were performed 
such that the difference of the secondary devices, B, compared to the criterion, A, divided by the 
average of the two devices [Difference (B – A) / Average 
𝐵+𝐴
2
)]. The results for EE, HR, BR 
during the continuous 40-minute light-to-moderate intensity are displayed in Figures 9, 10, 11, 
respectively.  
Figure 9 contains the results from the Bland-Altman plot for the Fitmate metabolic unit 
versus the Metria during the 40-minute continuous light-to-moderate intensity PA for EE. The 
results demonstrate that the Metria has a bias of -0.52 ± 1.72 kcals · minute
-1
 with 95% limits of 
agreement from -3.88 – 2.85 kcals · minute-1. This indicates that on average the Metria generally 
underestimates by 0.52 kcals · minute
-1
. 
Figure 9: Bland-Altman plot for the Fitmate metabolic unit versus Metria during the 40-
minute continuous light-to-moderate intensity physical activity intensity for Energy 
Expenditure 
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Figure 10 contains the results from the Bland-Altman plot for the Fitmate versus the 
Bioharness during the 40-minute continuous light-to-moderate intensity PA for HR. The results 
demonstrate that the Bioharness has a bias of 1.05 ± 8.48 bpm with 95% limits of agreement 
from -15.57 – 17.67 bpm. This indicates that on average the Bioharness generally overestimates 
by 1.05 bpm. 
 
Figure 10: Bland-Altman plot for the Fitmate metabolic unit versus Bioharness during the 
40-minute continuous light-to-moderate intensity physical activity for Heart Rate 
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Figure 11 contains the results from the Bland-Altman plot for the Fitmate metabolic unit 
versus the Bioharness during the 40-minute continuous light-to-moderate intensity PA for BR. 
The results demonstrate that the Bioharness has a bias of -0.02 ± 4.56 breaths/min with 95% 
limits of agreement from -8.96 – 8.92 breaths/min. This indicates that on average the Bioharness 
generally underestimates by 0.02 breaths/min. 
. 
Figure 11: Bland-Altman plot for the Fitmate metabolic unit versus Bioharness during the 
40-minute continuous light-to-moderate intensity physical activity for Breathing Rate 
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In addition to the Metria and Bioharness, the Garmin VivoFit 2 and Mio Fuse, were also 
examined during the continuous light-to-moderate intensity treadmill activity. The accuracy of 
the total EE reported from these devices was determined using a paired t-test analysis. The 
results are summarized in Table 19, along with the Mean ± SD for EE. A significant difference 
was observed for the Garmin device, compared to the Fitmate (p < 0.001). The statistical 
analyses should be interpreted with caution given the small samples size.  
  
Table 19: Accuracy and Reliability of Consumer Based Wearable Technology for Energy 
Expenditure during continuous light activity (Mean ± SD) 
A significant difference was observed for the Garmin device compared to the Fitmate (p<0.001). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Light-to-moderate Trial 1  
  N Fitmate Garmin N Fitmate Mio 
Grouped   5 355.19 ± 39.67 174.00 ± 28.53* 6 255.30 ± 55.80 277.00 ± 136.31 
 
Light-to-moderate Trial 2 
  N Fitmate Garmin N Fitmate Mio 
Grouped   2 324.17 ± 26.19 114.50 ± 54.45 1 419.93 496.00 
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2.5 Discussion  
The primary purpose of this study was to examine the validity of two high cost PA 
trackers, the Zephyr Bioharness and the Metria Armband by Vancive, to differentiate exercise 
intensities plus modalities using the following variables: EE (kcals · minute
-1
), HR (bpm), and 
BR (b/min). 
 
A secondary purpose was to also examine the validity of two low cost PA trackers 
to differentiate exercise intensities plus modalities using the following variables: EE (kcals · 
minute
-1
) and HR (bpm). It was hypothesized that EE recorded from the devices would 
accurately differentiate PA intensities and modalities within all wearable technology devices. 
The results from the statistical analyses support the hypothesis for the use of EE as a valid and 
reliable variable for the differentiation of i) PA intensity ranges and ii) continuous light-to-
moderate versus intermittent moderate-to-vigorous and vigorous-to-maximal circuit-based PA 
modalities. 
In order to determine validity across different wearable technology devices the 
researchers had to initially define an accurate comparator. Since the Fitmate metabolic unit was 
chosen as the comparator for this investigation, it was vital to determine the validity and 
reliability of the Fitmate metabolic unit at varying exercise intensity ranges. This was completed 
by having participants repeat the initial incremental-to-maximal VO2 protocol under the same 
conditions and sequencing using the criterion measure for VO2, the discrete component open 
circuit spirometry system and therefore a criterion estimate of EE (kcal·min
-1
). The results of 
these two completed trials were statistically tested and no significant differences were found, 
thus deeming the Fitmate as an appropriate comparator for assessing the validity and reliability 
of the Bioharness, Metria, Garmin and Mio devices. The Fitmate metabolic unit is designed to 
use the Polar Unit for the determination of HR. Therefore, the Polar unit was used during the two 
incremental-to maximal VO2 trials and was used as the criterion reference for HR’s obtained 
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from the Bioharness, Garmin and Mio devices. The metabolic unit, Cosmed Fitmate, and discrete 
component system, had good correlation for both VO2 (r = 0.92 ± 0.04) and BR r = 0.97 ± 0.03. 
The statistical analyses demonstrated that the HR from the various devices was only significantly 
different from the Polar unit at light-to-moderate intensity PA, but not practically significant, 
therefore, allowing the researchers to use the Fitmate during free-motion activity. The 
researchers had also completed multiple Bland-Altman analyses to indicate that these devices 
were operating within practically significant ranges based on the 95% Limits of Agreement.  
In addition to the statistical analyses, the researchers were able to confirm the PA 
intensity during the sessions by obtaining blood lactate samples from a subset of study 
participants. At rest, an individual’s blood lactate typically ranges between 0.5 to 2.2 mmol/L 
(Gollnik, 1986; McGee 1992). As an individual participates in more intense forms of PA, there 
will be an increase of metabolites and byproducts due to the greater reliance on the anaerobic 
system. At maximal intensities, an individual can have blood lactate values ranging between 20 
and 25 mmol/L (Mainwood, 1985). The blood lactate values during the continuous light-to-
moderate intensity PA were 1.61 ± 1.11 mmol/L, n = 48.  The blood lactate values during the 
intermittent moderate-to-vigorous circuit were 6.02 ± 4.00 mmol/L, n = 49. Therefore, the blood 
lactate values had confirmed the PA intensity from each of the respective exercise sessions. 
Furthermore, the researchers were also able to confirm the PA intensities during the 
sessions by live monitoring of the study participants heart rate from the Polar receiver and 
Bioharness and by asking the study participants to self-report their rating of perceived exertion 
using the original Borg subjective Rating of Perceived Exertion scale (RPE) (BORG, 1982).  The 
original Borg subjective RPE scale ranges from 6 to 20, where 6 is “very, very light” and 20 is 
“very, very hard”. Typically, at rest, individual’s self-report an RPE of 6. Once the individuals 
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began to exercise at a light-to-moderate intensity they self-reported an RPE ranging between 10 
to 13. During more vigorous bouts of PA, individuals self-reported an RPE ranging between 16 
to 20. During the investigation, the self-reported RPE values and their respective descriptors 
aligned with the both PA sessions, intermittent moderate-to-vigorous intensity circuit and 
continuous light-to-moderate intensity. Therefore, the PA intensity from each of the respective 
sessions was again reinforced by the self-reported RPE using the original Borg subjective ranges.  
The study outcomes revealed that during the  light-to-moderate intensity exercise session 
the i) EE, as assessed by the Metria, was significantly different from the Fitmate and on average 
overestimated by 0.64 kcals · minute
-1
, ii) HR, as assessed by the Bioharness, was significantly 
different from the Polar unit  and on average underestimated by 4.73 bpm and iii) BR, as 
measured by the Bioharness, was significantly different from the Fitmate metabolic unit and on 
average underestimated by 9.49 breathes/minute. This is summarized in (Table 20).  
The study outcomes also revealed that during the moderate-to-vigorous intensity exercise 
session the i) EE, as assessed by the Metria, was significantly different from the Fitmate with a 
mean overestimate of 0.33 kcals · minute
-1
, ii) HR, as assessed by the Bioharness, was not 
significantly different from the Polar Unit with a mean error of 0.6 bpm and iii) BR, as measured 
by the Bioharness, was significantly different from the Fitmate metabolic unit with a mean 
underestimate of 2.85 breathes/minute. This is summarized in (Table 20). 
Additionally, the study outcomes revealed that during the vigorous-to-maximal intensity 
exercise session the i) EE, as assessed by the Metria, was significantly different from the Fitmate 
with a mean underestimate of 1.78 kcals · minute
-1
, ii) HR, as assessed by the Bioharness, was 
significantly different from the Fitmate with a mean overestimate of 1.61 bpm and iii) BR, as 
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measured by the Bioharness, was significantly different with a mean underestimate of 5.61 
breathes/minute. This is summarized in (Table 20). 
It is important to note that, despite the statistical difference compared to the criterion 
measures, the estimates are still practically relevant, more commonly referred to as clinically 
significant. As shown in Table 20, this can be applied to the practical significance of the EE 
where a mean error of 1.78 kcals · minute
-1
 will not impose that much of a difference in a thirty 
minute vigorous-to-maximal intensity PA session, where the EE can be upwards of 13 kcals · 
minute
-1
. In reference to HR, a mean underestimate of 0.6 bpm in HR is not practically 
significant nor can most equipment measure to this degree of specificity. At most, an 
underestimate of 4.73 bpm at a moderate-to-vigorous intensity PA where the HR can range 
between 140-160 bpm, is still within the 95% Limits of Agreement.  
Table 20 contains a summary of the statistical significance, over or under reporting, 
device intensity estimation, and the corresponding practical significance during a thirty-minute 
workout for the Metria and Bioharness during all PA intensity ranges. The statistical significance 
values were taken from the paired t-test analyses completed during the incremental-to-maximum 
VO2. The results of the statistical analyses for all PA ranges were reflected during the 
incremental-to-maximum VO2. The over and under estimation is reported in reference to the 
Fitmate portable metabolic unit. The practical significance 95% CI is based on the results from 
the Bland-Altman analyses, respective to the PA intensity and is reported in EE kcals per minute 
(kcals · minute
-1
). The practical significance percent error, is the mean bias reported from the 
Bland-Altman analyses, divided by the mean value of the Fitmate portable metabolic unit, 
multiplied by 100. The practical application or impact is in reference to a thirty-minute workout. 
For EE, the kcals reported are total kcals that would be either over or under estimated for  a 
75 
 
thirty-minute exercise session. For HR, the value reported is in beats per minute and would 
represent an over or under estimation of that value every minute. For BR, the value reported is in 
breathes per minute and would represent an over or under estimation of that value every minute.  
 
 
Table 20: Summary table including PA intensity, device estimation, statistical significance 
and practical significance.  
Metria Energy Expenditure compared to Fitmate metabolic unit 
    
Intensity Over/
Under 
Statistical 
Significance 
Practical Significance 
(95% CI) 
(kcals · minute
-1
 ) 
Practical Significance 
(percent error) 
Practical 
Application for a 
30 minute 
workout) (kcals) 
Light-to-
moderate 
∧ p < 0.001 -2.91 – 3.46  4.39  8.4  
Moderate-to-
vigorous 
∧ p < 0.001 -2.59 – 3.87 5.99 19.2 
Vigorous-to-
maximal 
∨ p < 0.001 -7.22 – 3.65 12.99 -53.4 
 
 
 
 
Bioharness Breathing Rate compared to Fitmate metabolic unit 
    
Intensity Over/
Under 
Statistical 
Significance 
Practical Significance 
(95% CI) 
(breaths/min) 
Practical Significance 
(percent error) 
Practical 
Application 
(breaths/min) 
Light-to-
moderate 
∨ p < 0.05 -18.04 – 12.34 11.33 -2.85 
Moderate-to-
vigorous 
∨ p < 0.001 -32.96 – 13.98 24.31 -9.49 
Vigorous-to-
maximal 
∨ p < 0.001 -21.96 – 10.73 11.64 -5.61 
 
Bioharness Heart Rate compared to Polar Unit 
    
Intensity Over/
Under 
Statistical 
Significance 
Practical Significance 
(95% CI) 
(bpm) 
Practical Significance 
(percent error) 
Practical 
Application (bpm) 
Light-to-
moderate 
∨ p < 0.001 -16 – 15 0.5 0.6 
Moderate-to-
vigorous 
∨ p < 0.001 -26 – 17 3.06 -4.73 
Vigorous-to-
maximal 
∧ - -21 – 24 0.82 1.45 
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Based on the data obtained from the Fitmate metabolic unit at light-to-moderate intensity 
PA the average EE was 6.38 kcals · minute
-1
, which would result in a total EE of 191.4 kcals for 
a thirty-minute exercise session. Thus, an overestimation of 8.4 kcals from the Metria is only an 
error of 4.39%, which does not pose any threats to the PA tracking devices’ ability to 
differentiate light-to-moderate intensity PA. Moreover, during the moderate-to-vigorous intensity 
PA, the average EE was 10.68 kcals · minute
-1
, which would result in a total EE of 320.4 kcals 
for a thirty-minute exercise session. Thus, an overestimation of 19.2 kcals from the Metria in this 
same time frame will only cause an error of 5.99%, which does not pose any threats to the PA 
tracking devices’ ability to differentiate moderate-to-vigorous PA intensity. Also, during the 
vigorous-to-maximal intensity PA, the average EE was 13.70 kcals · minute
-1
, which would 
result in a total EE of 411 kcals for a thirty-minute exercise sessions. Thus, an underestimation of 
53.4 kcals from the Metria in this same time frame will only cause an error of 12.99%, which 
will also not pose any threats to the PA tracking devices’ ability to differentiate vigorous-to 
maximal PA intensity.  
As for the HR variable from the Polar unit, at light-to-moderate intensity PA the average 
HR was determined to be 116.57 bpm. Thus, an underestimation of 0.6 bpm from the Bioharness 
is only an error of 0.51%, which does not pose any threats to the PA tracking devices’ ability to 
differentiate light-to-moderate intensity PA. Moreover, during the moderate-to-vigorous intensity 
PA, the average HR was determined to be 154.77 bpm. Thus, an underestimation of 4.73 bpm 
from the Bioharness in this same time frame will only cause an error of 3.06%, which does not 
pose any threats to the PA tracking devices ability to differentiate moderate-to-vigorous intensity 
PA. Also, during the vigorous-to-maximal intensity PA, the average HR was determined to be 
176.80 bpm. Thus, an overestimation of 1.45 bpm from the Bioharness in this same time frame 
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will only cause an error of 0.82%, which does not pose any threats to the PA tracking devices’ 
ability to differentiate vigorous-to-maximal intensity PA.  
For the final secondary variable, BR, at light-to-moderate intensity PA the average BR 
was determined to be 25.14 breaths/min. Thus, an underestimation of 2.85 breaths/min from the 
Bioharness is only an error of 11.34%, which will not pose any threats to the PA tracking devices 
ability to differentiate light-to-moderate intensity PA. Moreover, during the moderate-to-
vigorous intensity PA, an individual’s BR would typically be 39.04 breaths/min. Thus, an 
underestimation of 9.49 breaths/min from the Bioharness in this same time frame will only cause 
an error of 24.31%, which will also not pose any threats to the PA tracking devices ability to 
differentiate moderate-to-vigorous intensity PA. Also, during the vigorous-to-maximal intensity 
PA, an individual’s HR would typically be 48.18 breaths/min. Thus, an underestimation of 5.61 
breaths/min from the Bioharness in this same time frame will only cause an error of 11.54%, 
which will also not pose any threats to the PA tracking devices ability to differentiate vigorous-
to-maximal intensity PA.  
It is important to note some of the setbacks pertaining to product limitations, as well as 
how they had potentially affected two of the variables of interest, HR and BR. The HR measure 
was effected when subjects were required to wear three chest bands to measure the exercise HR. 
In addition, the HR chest bands would at times move, throughout varying exercises and 
collection periods, resulting in occasional erroneous values. Study participants were only 
required to wear multiple chest bands when they were assigned to a group who wore an 
additional chest band for the Garmin VivoFit, the other two chest bands were from the 
Bioharness and Polar unit. Erroneous values were not observed when only two chest bands were 
worn. Moreover, the HR data pertaining to reliability could have also affected by natural day-to-
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day variations based on factors that the researchers could not control for such as; sleep duration 
and quality, hydration, caffeine, and familiarity of the exercise (Ewing, 1991; Achten, 2003). 
Also, due to technological design, the HR from some of the PA tracking devices experienced a 
lag time when the study participants were transitioning between different intensity exercises and 
movements, which could not be corrected for (Achten, 2003). 
It was observed that BR was at times also affected by product limitations when study 
participants were in prone positions or had moved from prone to standing. The transition 
between orthogonal planes had affected BR as of a result of the Bioharness measurement 
methods. The BR was measured in this device via stretch transducers built into the band, 
designed to pick up movements in the upper torso from inspiration and expiration. When the 
study participants were in ‘problematic’ positions the BR was at times lower than expected, due 
to the decreased band tension, resulting in missed breaths. This can be reinforced upon 
examining the difference in error between the continuous light-to-moderate intensity treadmill 
activity and intermittent moderate-to-vigorous intensity circuit activity. During the continuous 
light-to-moderate intensity treadmill activity, the movement between the orthogonal planes was 
minimal, and the study participant was simply required to walk on the treadmill. This minimal 
movement yield almost identical results for BR between the Fitmate and Bioharness, unlike the 
circuit activity. A simple but unlikely solution could be to pre-emptively over tighten the 
respective chest bands, but this may be uncomfortable and restricting for the study participants. 
Aside from the validity of this variable, it in it of itself is not a strong reflection of PA intensity. 
It is known that BR can be affected by a number of different factors such as the activity at hand, 
number and size of the working muscles, as well as the VO2. Typically, BR and intensity are 
assimilated through the talk test (Persinger, 2004). 
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Although the above variables may have been affected by these limitations, statistical 
analyses of the low cost Garmin VivoFit 2 and Mio Fuse indicate that these PA tracking devices  
provide valid estimates of EE but not HR during continuous light-to-moderate intensity steady 
state and circuit based moderate-to-vigorous intensity PA. As well, at certain points in the 
investigation the researchers were underpowered and unable to determine whether or not the low 
cost consumer based devices truly reported valid and reliable findings. The findings should be 
interpreted with caution given the small sample size. Despite being underpowered, the results of 
other investigations reveal similar outcomes, in terms of percent error (Lee, 2014). 
 In conclusion wearable technology that differentiates PA intensity and modalities 
appears most promising for estimates of EE and HR. Although the results for EE were at times 
statistically significant, it is important to note that the values are still within practical/clinical 
significance, thus supporting the hypothesis for the use of EE as a critical variable in the 
differentiation of PA intensity ranges and modalities. In order to enhance accuracy, the 
supplementation of an additional robust variable such as HR should be used in conjunction with 
EE to refine the differentiation of PA intensity ranges. While some variables may misclassify the 
PA intensity range, this could pose potential threats to clinical populations who may require 
more precise PA intensity monitoring while exercising. For example, the potential coupling of 
such devices with the AP to further improve blood glucose management for persons with T1D, 
whether they are habitually active or want to become more physically active. The results of this 
study build on those previously published supporting some differences in the EE reported from 
wearable technology devices. Based on the findings of this investigation it appears that, the 
higher cost PA tracking devices that track more physiological variables present more validity. 
Therefore, whether persons are interested in; becoming habitually active, increasing the current 
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level of PA, or persons with a chronic condition such as T1D, the higher cost PA trackers are the 
better choice given their ability to differentiate between PA intensities and modalities.  
 
2.6 Limitations  
During this investigation a number of set-backs were associated with product design, hardware 
malfunction, and ethical blood glucose cut-points. At times, device malfunction could have been 
due to either mechanical or natural and inevitable flaws (i.e. battery), causing some devices to 
not operate as intended. As of a result of this disruption, the data extracted from the Fitmate or 
Metria was inoperative and resulted in lower sample sizes at times. The suspected cause of 
malfunction in the Fitmate could have been due to an exhausted oxygen sensor, damaged oxygen 
sample line, or file saving errors. Although the former can be at times avoided, the latter could 
not be. At various times, the researchers were able to determine whether or not the Fitmate was 
operating accurately and act accordingly, but at others it was unavoidable, as this issue had 
arisen mid-collection. The issue was primarily unavoidable during the intermittent moderate-to-
vigorous intensity circuit collection as the study participants had worn the Fitmate in a closed 
and secured backpack.  
Malfunction in the Metria was unavoidable and only discovered upon data upload. This is 
due to the inability of the device to communicate with an external component until it was 
removed from the body. Given that some study participants had worn the device for up to 72+ 
hours unsupervised, proper device care and management was out of the researchers control. The 
device was intended to be sweat and water-resistant but had proven to be otherwise at times. 
Another potential cause of malfunction in the Metria could have been due to battery life. Since 
the devices come in a stand-by mode from the manufacturer, some devices may have had a 
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shorter life remaining due to the already consumed battery. Depending on the situation, even 
though the battery had died, the researchers were able to extract some but not all of the collected 
data.  The researchers had attempted to solve this issue by affixing two Metria units above each 
other, but this proved to be rather expensive and at times, unnecessary.  
 Given the special subset population and strict ethical cut-offs in this investigation, there 
were times that the data collection had to be prematurely terminated to avoid ethical violation, 
even though this may have not lead to any adverse effects. Premature termination of the data 
collection primarily occurred during the light treadmill based continuous activity for reasons 
stated above, but had also occurred in one subject during the circuit. Although glycemic 
fluctuations may have been instigated from the activity, the researchers were unable to control 
for this due to the complexity of the disease, thus dietary corrections, diversity of physiological 
and physical fitness and exercise tolerance of the study participants.  
 
2.7 Implications 
 Through this investigation the researchers were able to share their newly found 
knowledge with the scientific community and those interested in exercise as a primary disease 
prevention and secondary disease management strategy. This study was precipitated by the needs 
of persons interested in developing an AP. These persons were seeking to obtain electrical 
signals that aligned with real-time physiological responses obtained during varying PA intensity 
ranges and modalities. These findings may play an integral part in customizing primary disease 
prevention and secondary disease prevention PA prescriptions as well as, shine light on the novel 
uses of currently available body sensing technology. The results of this investigation aid in the 
understanding PA prescriptions, as well as, improve compliance to the PA prescription, with a 
goal to enhance the PA intervention. Given that lack of time is often cited as a justification for 
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sedentarism, individuals with the ability to quantify their PA participation effort could be less 
hesitant to justify lack of time, upon experiencing the simplicity of expending more energy. 
Generally, people tend to seek rewards for their accomplishments, and are often turned away 
when they feel otherwise. The simplicity and convenience of some currently available wearable 
technology devices can aid in bridging this gap of immediate gratification and feeling of 
accomplishment from PA participation. With further research in this area, wearable technology 
devices that are able to accurately differentiate varying PA intensities and modalities can 
successfully be utilized for clinical purposes (AP), and more accurately in primary disease 
prevention and secondary disease management. 
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